[{"user":"Somatic-cell selection is a major determinant of the blood-cell phenotype in heterozygotes for glucose-6-phosphate dehydrogenase mutations causing severe enzyme deficiency.X-chromosome inactivation in mammals is regarded as an essentially random process, but the resulting somatic-cell mosaicism creates the opportunity for cell selection.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"enzyme deficiency\"}]"},{"user":"In most people with red-blood-cell glucose-6-phosphate dehydrogenase (G6PD) deficiency, the enzyme-deficient phenotype is only moderately expressed in nucleated cells.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"glucose-6-phosphate dehydrogenase (G6PD) deficiency\"}]"},{"user":"However, in a small subset of hemizygous males who suffer from chronic nonspherocytic hemolytic anemia, the underlying mutations (designated class I) cause more-severe G6PD deficiency, and this might provide an opportunity for selection in heterozygous females during development.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"chronic nonspherocytic hemolytic anemia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"G6PD deficiency\"}]"},{"user":"In order to test this possibility we have analyzed four heterozygotes for class I G6PD mutations  two with G6PD Portici (1178G-- > A) and two with G6PD Bari (1187C-- > T).We found that in fractionated blood cell types (including erythroid, myeloid, and lymphoid cell lineages) there was a significant excess of G6PD-normal cells.","assistant":"]"},{"user":"The significant concordance that we have observed in the degree of imbalance in the different blood-cell lineages indicates that a selective mechanism is likely to operate at the level of pluripotent blood stem cells.Thus, it appears that severe G6PD deficiency\nThe ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"G6PD deficiency\"}, {\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}]"},{"user":"The product of the ataxia-telangiectasia gene (ATM) was identified by using an antiserum developed to a peptide corresponding to the deduced amino acid sequence.The ATM protein is a single, high-molecular weight protein predominantly confined to the nucleus of human fibroblasts, but is present in both nuclear and microsomal fractions from human lymphoblast cells and peripheral blood lymphocytes.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}]"},{"user":"ATM protein levels and localization remain constant throughout all stages of the cell cycle.Truncated ATM protein was not detected in lymphoblasts from ataxia-telangiectasia\nMolecular basis for Duarte and Los Angeles variant galactosemia.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"CompositeMention\", \"entity\": \"Duarte and Los Angeles variant galactosemia\"}]"},{"user":"Human orythrocytes that are homozygous for the Duarte enzyme variant of galactosemia (D\/D) have a characteristic isoform on isoelectric focusing and 50% reduction in galactose-1-phosphate uridyltransferase (GALT) enzyme activity.The Duarte biochemical phenotype has a molecular genotype of N314D\/N314D.The characteristic Duarte isoform is also associated with a variant called the \" Los Angeles (LA) phenotype, \" which has increased GALT enzyme activity.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Duarte enzyme variant of galactosemia\"}]"},{"user":"We evaluated GALT enzyme activity and screened the GALT genes of 145 patients with one or more N314D-containing alleles.We found seven with the LA biochemical phenotype, and all had a 1721C-- > T transition in exon 7 in cis with the N314D missense mutation.The 1721C-- > T transition is a neutral polymorphism for leucine at amino acid 218 (L218L).","assistant":"]"},{"user":"In pedigree analyses, this 1721C-- > T transition segregated with the LA phenotype of increased GALT activity in three different biochemical phenotypes (LA\/N, LA\/G, and LA\/D).To determine the mechanism for increased activity of the LA variant, we compared GALT mRNA, protein abundance, and enzyme thermal stability in lymphoblast cell lines of D and LA phenotypes with comparable genotypes.GALT protein abundance was increased in LA compared to D alleles, but mRNA was similar among all genotypes.","assistant":"]"},{"user":"When LA\/D and D\/D GALT biochemical phenotypes were compared to N\/N GALT phenotypes, both had 50%, as compared to 21%, reduction in GALT activity in the wild type (N\/N) after exposure at identical initial enzyme activity to 50 degrees C for 15 min.","assistant":"]"},{"user":"We conclude that the codon change N314D in cis with the base-pair transition 1721C-- > T produces the LA variant of galactosemia\nAn intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-eye disease).The first step in the splicing of an intron from nuclear precursors of mRNA results in the formation of a lariat structure.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"LA variant of galactosemia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"inherited human disorder\"}, {\"category\": \"SpecificDisease\", \"entity\": \"fish-eye disease\"}]"},{"user":"A distinct intronic nucleotide sequence, known as the branchpoint region, plays a central role in this process.We here describe a point mutation in such a sequence.Three sisters were shown to suffer from fish-eye disease (FED), a disorder which is caused by mutations in the gene coding for lecithin  cholesterol acyltransferase (LCAT).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"fish-eye disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"FED\"}]"},{"user":"Sequencing of the LCAT gene of all three probands revealed compound heterozygosity for a missense mutation in exon 4 which is reported to underlie the FED phenotype, and a point mutation located in intron 4 (IVS4  T-22C).By performing in vitro expression of LCAT minigenes and reverse transcriptase PCR on mRNA isolated from leukocytes of the patient, this gene defect was shown to cause a null allele as the result of complete intron retention.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"FED\"}]"},{"user":"In conclusion, we demonstrated that a point mutation in a lariat branchpoint consensus sequence causes a null allele in a patient with FED\nGenetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2.The common hereditary forms of breast cancer have been largely attributed to the inheritance of mutations in the BRCA1 or BRCA2 genes.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"FED\"}, {\"category\": \"SpecificDisease\", \"entity\": \"hereditary breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"However, it is not yet clear what proportion of hereditary breast cancer is explained by BRCA1 and BRCA2 or by some other unidentified susceptibility gene (s).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"hereditary breast cancer\"}]"},{"user":"We describe the proportion of hereditary breast cancer explained by BRCA1 or BRCA2 in a sample of North American hereditary breast cancers and assess the evidence for additional susceptibility genes that may confer hereditary breast or ovarian cancer risk.Twenty-three families were identified through two high-risk breast cancer research programs.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"hereditary breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"hereditary breast cancers\"}, {\"category\": \"Modifier\", \"entity\": \"hereditary breast or ovarian cancer\"}, {\"category\": \"Modifier\", \"entity\": \"breast cancer\"}]"},{"user":"Genetic analysis was undertaken to establish linkage between the breast or ovarian cancer cases and markers on chromosomes 17q (BRCA1) and 13q (BRCA2).Mutation analysis in the BRCA1 and BRCA2 genes was also undertaken in all families.The pattern of hereditary cancer in 14 (61%) of the 23 families studied was attributed to BRCA1 by a combination of linkage and mutation analyses.No families were attributed to BRCA2.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"breast or ovarian cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"hereditary cancer\"}]"},{"user":"Five families (22%) provided evidence against linkage to both BRCA1 and BRCA2.No BRCA1 or BRCA2 mutations were detected in these five families.The BRCA1 or BRCA2 status of four families (17%) could not be determined.BRCA1 and BRCA2 probably explain the majority of hereditary breast cancer that exists in the North American population.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"hereditary breast cancer\"}]"},{"user":"However, one or more additional genes may yet be found that explain some proportion of hereditary breast cancer\nThe tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse.Mutations of the BRCA1 gone in humans are associated with predisposition to breast and ovarian cancers.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"hereditary breast cancer\"}, {\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"CompositeMention\", \"entity\": \"breast and ovarian cancers\"}]"},{"user":"We show here that Brca1 +\/- mice are normal and fertile and lack tumors\nFusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"tumors\"}, {\"category\": \"SpecificDisease\", \"entity\": \"alveolar rhabdomyosarcoma\"}]"},{"user":"Chromosomal translocations identified in hematopoietic and solid tumors result in deregulated expression of protooncogenes or creation of chimeric proteins with tumorigenic potential.In the pediatric solid tumor alveolar rhabdomyosarcoma, a consistent t (2; 13) (q35; q14) or variant t (1; 13) (p36; q14) translocation generates PAX3-FKHR or PAX7-FKHR fusion proteins, respectively.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"hematopoietic and solid tumors\"}, {\"category\": \"DiseaseClass\", \"entity\": \"solid tumor\"}, {\"category\": \"SpecificDisease\", \"entity\": \"alveolar rhabdomyosarcoma\"}]"},{"user":"In this report, we demonstrate that in addition to functional alterations these translocations are associated with fusion product overexpression.Furthermore, PAX3-FKHR and PAX7-FKHR overexpression occurs by distinct mechanisms.Transcription of PAX3-FKHR is increased relative to wild-type PAX3 by a copy number-independent process.In contrast, PAX7-FKHR overexpression results from fusion gene amplification.","assistant":"]"},{"user":"Thus, gene-specific mechanisms were selected to overexpress PAX3-FKHR and PAX7-FKHR in alveolar rhabdomyosarcoma\nPleiotropic defects in ataxia-telangiectasia protein-deficient mice.We have generated a mouse model for ataxia-telangiectasia by using gene targeting to generate mice that do not express the Atm protein.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"alveolar rhabdomyosarcoma\"}, {\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ataxia-telangiectasia\"}]"},{"user":"Atm-deficient mice are retarded in growth, do not produce mature sperm, and exhibit severe defects in T cell maturation while going on to develop thymomas.Atm-deficient fibroblasts grow poorly in culture and display a high level of double-stranded chromosome breaks.Atm-deficient thymocytes undergo spontaneous apoptosis in vitro significantly more than controls.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"thymomas\"}]"},{"user":"Atm-deficient mice then exhibit many of the same symptoms found in ataxia-telangiectasia\nMuscle expression of glucose-6-phosphate dehydrogenase deficiency in different variants.Muscle expression of G6PD deficiency\nPTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"glucose-6-phosphate dehydrogenase deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"G6PD deficiency\"}, {\"category\": \"CompositeMention\", \"entity\": \"brain, breast, and prostate cancer\"}]"},{"user":"Mapping of homozygous deletions on human chromosome 10q23 has led to the isolation of a candidate tumor suppressor gene, PTEN, that appears to be mutated at considerable frequency in human cancers.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancers\"}]"},{"user":"In preliminary screens, mutations of PTEN were detected in 31% (13\/42) of glioblastoma cell lines and xenografts, 100% (4\/4) of prostate cancer cell lines, 6% (4\/65) of breast cancer cell lines and xenografts, and 17% (3\/18) of primary glioblastomas.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"glioblastoma\"}, {\"category\": \"Modifier\", \"entity\": \"prostate cancer\"}, {\"category\": \"Modifier\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"primary glioblastomas\"}]"},{"user":"The predicted PTEN product has a protein tyrosine phosphatase domain and extensive homology to tensin, a protein that interacts with actin filaments at focal adhesions.","assistant":"]"},{"user":"These homologies suggest that PTEN may suppress tumor cell growth by antagonizing protein tyrosine kinases and may regulate tumor cell invasion and metastasis\nSomatic alterations of the DPC4 gene in human colorectal cancers in vivo.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"DiseaseClass\", \"entity\": \"metastasis\"}, {\"category\": \"SpecificDisease\", \"entity\": \"colorectal cancers\"}]"},{"user":"BACKGROUND & AIMS  The chromosome region 18q21 has been shown to be frequently deleted in colorectal cancers, and such frequent allelic loss is a hallmark of the presence of a tumor-suppressor gene.The DPC4 gene, which is located at 18q21, has been identified as a tumor-suppressor gene from examination of pancreatic cancers.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"colorectal cancers\"}, {\"category\": \"SpecificDisease\", \"entity\": \"pancreatic cancers\"}]"},{"user":"The aim of the present study was to determine if it might also be altered in colorectal cancers.METHODS  Mutation analyses of the DPC4 gene were performed on complementary DNA samples from 31 primary colorectal cancer specimens using a combination of polymerase chain reaction, single-strand conformation polymorphism, and DNA sequencing.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"colorectal cancers\"}, {\"category\": \"Modifier\", \"entity\": \"colorectal cancer\"}]"},{"user":"RESULTS  Four missense mutations producing amino acid substitutions and a somatic 12-base pair deletion in the coding region of the DPC4 gene were detected in the 31 cancers (16%; 5 of 31).","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"cancers\"}]"},{"user":"CONCLUSIONS  The DPC4 gene may play a role as a tumor-suppressor gene in a fraction of colorectal cancers; however, while allelic loss at 18q21 is very often seen in colorectal cancers\nComplete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1.Over 100 distinct disease-associated mutations have been identified in the breast-ovarian cancer susceptibility gene BRCA1.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"colorectal cancers\"}, {\"category\": \"SpecificDisease\", \"entity\": \"colorectal cancers\"}, {\"category\": \"Modifier\", \"entity\": \"breast-ovarian cancer\"}]"},{"user":"Loss of the wild-type allele in > 90% of tumors from patients with inherited BRCA1 mutations indicates tumor suppressive function.The low incidence of somatic mutations suggests that BRCA1 inactivation in sporadic tumors\nType II human complement C2 deficiency.Allele-specific amino acid substitutions (Ser189 --> Phe; Gly444 --> Arg) cause impaired C2 secretion.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"tumors\"}, {\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tumors\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Type II human complement C2 deficiency\"}]"},{"user":"Type II complement protein C2 deficiency is characterized by a selective block in C2 secretion.The Type II C2 null allele (C2Q0) is linked to two major histocompatibility haplotypes (MHC) that differ from the MHC of the more common Type I C2 deficiency.To determine the molecular basis of Type II deficiency the two Type II C2Q0 genes were isolated and transfected separately into L-cells.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Type II complement protein C2 deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Type I C2 deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Type II deficiency\"}]"},{"user":"Subsequent molecular biology, biosynthetic, and immunofluorescence studies demonstrated that C2 secretion is impaired in Type II C2 deficiency\nTargeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Type II C2 deficiency\"}, {\"category\": \"DiseaseClass\", \"entity\": \"growth retardation\"}, {\"category\": \"SpecificDisease\", \"entity\": \"chromosomal fragmentation during meiosis\"}, {\"category\": \"DiseaseClass\", \"entity\": \"immune defects\"}, {\"category\": \"SpecificDisease\", \"entity\": \"thymic lymphoma\"}]"},{"user":"ATM, the gene mutated in the inherited human disease ataxia-telangiectasia, is a member of a family of kinases involved in DNA metabolism and cell-cycle checkpoint control.To help clarify the physiological roles of the ATM protein, we disrupted the ATM gene in mice through homologous recombination.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"inherited human disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ataxia-telangiectasia\"}]"},{"user":"Initial evaluation of the ATM knockout animals indicates that inactivation of the mouse ATM gene recreates much of the phenotype of ataxia-telangiectasia.The homozygous mutant (ATM-\/-) mice are viable, growth-retarded, and infertile.The infertility of ATM-\/- mice results from meiotic failure.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"infertility\"}]"},{"user":"Meiosis is arrested at the zygotene\/pachytene stage of prophase I as a result of abnormal chromosomal synapsis and subsequent chromosome fragmentation.Immune defects also are evident in ATM-\/- mice, including reduced numbers of B220 + CD43- pre-B cells, thymocytes, and peripheral T cells, as well as functional impairment of T-cell-dependent immune responses.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"Immune defects\"}]"},{"user":"The cerebella of ATM-\/- mice appear normal by histologic examination at 3 to 4 months and the mice have no gross behavioral abnormalities.The majority of mutant mice rapidly develop thymic lymphomas and die before 4 months of age.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"behavioral abnormalities\"}, {\"category\": \"SpecificDisease\", \"entity\": \"thymic lymphomas\"}]"},{"user":"These findings indicate that the ATM gene product plays an essential role in a diverse group of cellular processes, including meiosis, the normal growth of somatic tissues, immune development, and tumor\nThe 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"tumor\"}]"},{"user":"To begin to address the hypothesis that abnormal regulation of the breast\/ovarian cancer\natm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"breast\/ovarian cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"acute radiation toxicity\"}]"},{"user":"Mutations in atm and p53 cause the human cancer-associated diseases ataxia-telangiectasia and Li-Fraumeni syndrome, respectively.The two genes are believed to interact in a number of pathways, including regulation of DNA damage-induced cell-cycle checkpoints, apoptosis and radiation sensitivity, and cellular proliferation.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"cancer-associated diseases\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Li-Fraumeni syndrome\"}]"},{"user":"Atm-null mice, as well as those null for p53, develop mainly T-cell lymphomas, supporting the view that these genes have similar roles in thymocyte development.To study the interactions of these two genes on an organismal level, we bred mice heterozygous for null alleles of both atm and p53 to produce all genotypic combinations.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"T-cell lymphomas\"}]"},{"user":"Mice doubly null for atm and p53 exhibited a dramatic acceleration of tumour formation relative to singly null mice, indicating that both genes collaborate in a significant manner to prevent tumorigenesis.With respect to their roles in apoptosis, loss of atm rendered thymocytes only partly resistant to irradiation-induced apoptosis, whereas additional loss of p53 engendered complete resistance.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"tumour\"}]"},{"user":"This implies that the irradiation-induced atm and p53 apoptotic pathways are not completely congruent.","assistant":"]"},{"user":"Finally-and in contrast to prior predictions-atm and p53 do not appear to interact in acute radiation toxicity, suggesting a separate atm effector pathway for this DNA damage response and having implications for the prognosis and treatment of human tumours\nMolecular bases of C7 deficiency: three different defects.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"acute radiation toxicity\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tumours\"}, {\"category\": \"SpecificDisease\", \"entity\": \"C7 deficiency\"}]"},{"user":"The molecular basis of C7 deficiency has been investigated in two Irish families and a number of Israeli families of Moroccan Sephardic Jewish origin.Exon PCR and sequencing revealed a heterozygous point mutation at the 3 splice acceptor site of intron 1 in one Irish family.In the other Irish family, exons 7 and 8 failed to amplify and they were shown to be deleted.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"C7 deficiency\"}]"},{"user":"Marker haplotype studies of the C6 and C7 gene region and Southern blots show that the Irish family with the splice defect also segregate for the deletion, which is not easily detected in heterozygotes.The Israeli C7-deficient\nIdentification of WASP mutations, mutation hotspots and genotype-phenotype disparities in 24 patients with the Wiskott-Aldrich syndrome.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"C7-deficient\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Wiskott-Aldrich syndrome\"}]"},{"user":"The Wiskott-Aldrich syndrome (WAS), an X-linked immunodeficiency disease caused by mutation in the recently isolated gene encoding WAS protein (WASP), is known to be associated with extensive clinical heterogeneity.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Wiskott-Aldrich syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"WAS\"}, {\"category\": \"DiseaseClass\", \"entity\": \"X-linked immunodeficiency disease\"}, {\"category\": \"Modifier\", \"entity\": \"WAS\"}]"},{"user":"Cumulative mutation data have revealed that WASP genotypes are also highly variable among WAS patients, but the relationship of phenotype with genotype in this disease remains unclear.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"WAS\"}]"},{"user":"To address this issue we characterized WASP mutations in 24 unrelated WAS patients, including 18 boys with severe classical WAS and 6 boys expressing mild forms of the disease, and then examined the degree of correlation of these as well as all previously published WASP mutations with disease severity.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"WAS\"}, {\"category\": \"SpecificDisease\", \"entity\": \"WAS\"}]"},{"user":"By analysis of these compiled mutation data, we demonstrated clustering of WASP mutations within the four most N-terminal exons of the gene and also identified several sites within this region as hotspots for WASP mutation.These characteristics were observed, however, in both severe and mild cases of the disease.","assistant":"]"},{"user":"Similarly, while the cumulative data revealed a predominance of missense mutations among the WASP gene lesions observed in boys with isolated thrombocytopenia, missense mutations were not exclusively associated with milder WAS phenotypes, but also comprised a substantial portion (38%) of the WASP gene defects found in patients with severe disease.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"isolated thrombocytopenia\"}, {\"category\": \"Modifier\", \"entity\": \"WAS\"}]"},{"user":"These findings, as well as the detection of identical WASP mutations in patients with disparate phenotypes, reveal a lack of phenotype concordance with genotype in WAS\nIdentification and chromosomal localization of Atm, the mouse homolog of the ataxia-telangiectasia gene.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"WAS\"}, {\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}]"},{"user":"Atm, the mouse homolog of the human ATM gene defective in ataxia-telangiectasia (A-T\nMutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair.Many human tumours have length alterations in repetitive sequence elements.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"A-T\"}, {\"category\": \"SpecificDisease\", \"entity\": \"endometrial cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tumours\"}]"},{"user":"Although this microsatellite instability has been attributed to mutations in four DNA mismatch repair genes in hereditary nonpolyposis colorectal cancer (HNPCC) kindreds, many sporadic tumours exhibit instability but no detectable mutations in these genes.It is therefore of interest to identify other genes that contribute to this instability.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"microsatellite instability\"}, {\"category\": \"Modifier\", \"entity\": \"hereditary nonpolyposis colorectal cancer\"}, {\"category\": \"Modifier\", \"entity\": \"HNPCC\"}, {\"category\": \"DiseaseClass\", \"entity\": \"sporadic tumours\"}]"},{"user":"In yeast, mutations in several genes, including RTH and MSH3, cause microsatellite instability.Thus, we screened 16 endometrial carcinomas with microsatellite instability for alterations in FEN1 (the human homolog of RTH) and in MSH3 (refs 12-14).Although we found no FEN1 mutations, a frameshift mutation in MSH3 was observed in an endometrial carcinoma and in an endometrial carcinoma cell line.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"endometrial carcinomas\"}, {\"category\": \"SpecificDisease\", \"entity\": \"endometrial carcinoma\"}, {\"category\": \"Modifier\", \"entity\": \"endometrial carcinoma\"}]"},{"user":"Extracts of the cell line were deficient in repair of DNA substrates containing mismatches or extra nucleotides.Introducing chromosome 5, encoding the MSH3 gene, into the mutant cell line increased the stability of some but not all microsatellites.Extracts of these cells repaired certain substrates containing extra nucleotides, but were deficient in repair of those containing mismatches or other extra nucleotides.","assistant":"]"},{"user":"A subsequent search revealed a second gene mutation in HHUA cells, a missense mutation in the MSH6 gene.Together the data suggest that the MSH3 gene encodes a product that functions in repair of some but not all pre-mutational intermediates, its mutation in tumours\nKniest dysplasia: Dr. W. Kniest, his patient, the molecular defect.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"tumours\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Kniest dysplasia\"}]"},{"user":"Kniest dysplasia is a severe chondrodysplasia caused by the defective formation of type II collagen.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Kniest dysplasia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"chondrodysplasia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"defective formation of type II collagen\"}]"},{"user":"We report about Dr. Kniest, who first described the condition in 1952, and his patient, who, at the age of 50 years is severely handicapped with short stature, restricted joint mobility, and blindness but is mentally alert and leads an active life.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"severely handicapped\"}, {\"category\": \"DiseaseClass\", \"entity\": \"short stature\"}, {\"category\": \"DiseaseClass\", \"entity\": \"restricted joint mobility\"}, {\"category\": \"DiseaseClass\", \"entity\": \"blindness\"}]"},{"user":"Molecular analysis of the patients DNA showed a single base (G) deletion involving the GT dinucleotide at the start of intron 18 destroying a splice site of the COL2A1 gene.This is in accordance with molecular findings in other patients with Kniest dysplasia\nAshkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Kniest dysplasia\"}]"},{"user":"BRCA1 and BRCA2 are the two major identified causes of inherited breast cancer, with mutations in either gene conferring up to 80-90% lifetime risk of breast cancer in carrier females.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"inherited breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"Mutations in BRCA1 account for approximately 45% of familial breast cancer and 90% of inherited breast\/ovarian cancer, whereas mutations in BRCA2 account for a comparable percentage of inherited breast cancer cases.Over 85 distinct BRCA1 mutations and a growing list of BRCA2 mutations have been identified, with the majority resulting in protein truncation.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"familial breast cancer\"}, {\"category\": \"CompositeMention\", \"entity\": \"inherited breast\/ovarian cancer\"}, {\"category\": \"Modifier\", \"entity\": \"inherited breast cancer\"}]"},{"user":"A specific BRCA1 mutation, 185delAG, has a reported increased carrier frequency of approximately 0.9% in the Ashkenazi Jewish population, but is also found in rare non-Jewish patients with a different haplotype.The 6174delT mutation in BRCA2 was recently identified as a frequent mutation in 8 out of 107 Ashkenazi Jewish women diagnosed with breast cancer by age 50 (ref.8), as well as in three Ashkenazi male breast cancer patients.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"Modifier\", \"entity\": \"male breast cancer\"}]"},{"user":"We have conducted a large-scale population study to investigate the prevalence of specific BRCA1 and BRCA2 mutations in Ashkenazi Jewish individuals who were unselected for breast cancer.BRCA1 mutation screening on approximately 3, 000 Ashkenazi Jewish samples determined a carrier frequency of 1.09% for the 185delAG mutation and 0.13% for the 5382insC mutation.BRCA2 analysis on 3, 085 individuals from the same population showed a carrier frequency of 1.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"52% for the 6174delT mutation.This expanded population-based study confirms that the BRCA1 185delAG mutation and the BRCA2 6174delT mutation constitute the two most frequent mutation alleles predisposing to hereditary breast cancer\nMapping the homolog of the human Rb1 gene to chromosome 14 of higher primates.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"hereditary breast cancer\"}]"},{"user":"The Rb1 gene has been implicated with retinoblastoma\nDifficulties in the ascertainment of C9 deficiency: lessons to be drawn from a compound heterozygote C9-deficient subject.A group of patients with long-surviving mismatched kidney allografts were investigated for complement function using haemolytic assays in agarose gels.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"retinoblastoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"C9 deficiency\"}, {\"category\": \"Modifier\", \"entity\": \"C9-deficient\"}]"},{"user":"One patient was found to have no alternative pathway activity but a low normal classical pathway.Surprisingly, investigation revealed that the patients complement was normal for all components except C9, which was functionally absent.The patient was shown to be heterozygous for DNA markers in the C6, C7 and C9 region of chromosome 5 and therefore appears to be a compound heterozygote for two uncharacterized C9 deficiency genes.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"C9 deficiency\"}]"},{"user":"Serological analysis by ELISA revealed that he has trace concentrations of a non-functional C9 molecule.Western blot analysis was not sufficiently sensitive to permit detection of this molecule.We hypothesize that the patient is heterozygous for a complete deficiency of C9 and for a gene directing hyposynthesis of a defective C9.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"complete deficiency of C9\"}]"},{"user":"We also suggest that C9 deficiency\nModerate intergenerational and somatic instability of a 55-CTG repeat in transgenic mice.Myotonic dystrophy (DM) is associated with the expansion of a (CTG) n trinucleotide repeat in the 3 untranslated region (UTR) of the DM protein kinase gene (DMPK).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"C9 deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Myotonic dystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DM\"}, {\"category\": \"Modifier\", \"entity\": \"DM\"}]"},{"user":"The (CTG) n repeat is polymorphic and varies in size between 5 and 37 repeats in unaffected individuals whereas in affected patients there are between 50 and 4, 000 CTGs.The size of the (CTG) n repeat, which increases through generations, generally correlates with clinical severity and age of onset.The instability of the CTG repeat appears to depend on its size as well as on the sex of the transmitting parent.","assistant":"]"},{"user":"Moreover, mitotic instability analysis of different human DM\nMutations in the arginine-rich protein gene (ARP) in pancreatic cancer.The ARP gene encodes a highly conserved arginine-rich protein from chromosomal band 3p21.1 1.At the cytogenetic level this region is frequently deleted in a variety of different solid tumors, although not in pancreatic cancer.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"DM\"}, {\"category\": \"SpecificDisease\", \"entity\": \"pancreatic cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"solid tumors\"}, {\"category\": \"SpecificDisease\", \"entity\": \"pancreatic cancer\"}]"},{"user":"We have reported the presence of a specific mutation (ATG50-- > AGG) or deletion of codon 50 of the ARP gene in different tumor types (Shridhar et al., 1996, 1996a).In the present study, we have observed mutations involving codon 50 in 11 of 37 pancreatic tumors.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"tumor types\"}, {\"category\": \"SpecificDisease\", \"entity\": \"pancreatic tumors\"}]"},{"user":"The frequency of codon 50 mutation is roughly the same in pancreatic tumors as in the other types of tumors previously examined.In addition, we have detected mutations at codon 51 in multiple PCR subclones in two other pancreatic tumors.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"pancreatic tumors\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tumors\"}, {\"category\": \"SpecificDisease\", \"entity\": \"pancreatic tumors\"}]"},{"user":"Mutations in the ARP gene are thus commonly observed in pancreatic cancer, as well as many other cancers\nHeterogeneity in Schwartz-Jampel chondrodystrophic myotonia.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"pancreatic cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancers\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Schwartz-Jampel chondrodystrophic myotonia\"}]"},{"user":"The Schwartz-Jampel syndrome (SJS; chondrodystrophic myotonia; McK 255, 800) is a recessively inherited condition defined by myotonia, short stature, and bone dysplasia.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Schwartz-Jampel syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"SJS\"}, {\"category\": \"SpecificDisease\", \"entity\": \"chondrodystrophic myotonia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"recessively inherited condition\"}, {\"category\": \"DiseaseClass\", \"entity\": \"myotonia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"short stature\"}, {\"category\": \"DiseaseClass\", \"entity\": \"bone dysplasia\"}]"},{"user":"Genetic linkage between SJS and chromosomal region 1q36-34 has been observed in several families, but the gene has not yet been identified.We studied the clinical and radiological features in 81 patients from the literature and 5 own patients trying to identify distinct subgroups.In addition, we tested genetic linkage to the SJS locus on chromosome 1 in one family with two affected sibs.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"SJS\"}, {\"category\": \"Modifier\", \"entity\": \"SJS\"}]"},{"user":"We found that a group of patients have mild skeletal changes which may be secondary consequences of myotonia, while another group of patients appear to have primary bone dysplasia with myotonia.Within this latter group, there are differences in age of manifestation, clinical course and pattern of bone changes.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"myotonia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"bone dysplasia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"myotonia\"}]"},{"user":"We tentatively isolate three different types of SJS  type 1A, usually recognized in childhood, with moderate bone dysplasia, corresponding to the original descriptions of Schwartz, Jampel and Aberfeld; type 1B, similar to type 1A but recognizable at birth, with more pronounced bone dysplasia resembling Kniest dysplasia; and type 2, manifest at birth, with increased mortality and bone dysplasia resembling Pyle disease.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"SJS  type 1A\"}, {\"category\": \"DiseaseClass\", \"entity\": \"bone dysplasia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"bone dysplasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Kniest dysplasia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"bone dysplasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Pyle disease\"}]"},{"user":"Genetic analysis of the family with two sibs affected by SJS type 2 showed evidence against linkage to chromosome 1p36-34.CONCLUSIONS  SJS is clinically and radiologically heterogeneous.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"SJS type 2\"}, {\"category\": \"SpecificDisease\", \"entity\": \"SJS\"}]"},{"user":"The causes of heterogeneity are not known yet but are likely to include both different mutations at the SJS locus on chromosome 1 and the presence of a second SJS\nX-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"SJS\"}, {\"category\": \"Modifier\", \"entity\": \"SJS\"}, {\"category\": \"SpecificDisease\", \"entity\": \"X-linked adrenoleukodystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Addison's disease\"}]"},{"user":"X-Linked adrenoleukodystrophy (ALD) is a genetic disease associated with demyelination of the central nervous system, adrenal insufficiency, and accumulation of very long chain fatty acids in tissue and body fluids.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"X-Linked adrenoleukodystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ALD\"}, {\"category\": \"DiseaseClass\", \"entity\": \"genetic disease\"}, {\"category\": \"DiseaseClass\", \"entity\": \"demyelination of the central nervous system\"}, {\"category\": \"DiseaseClass\", \"entity\": \"adrenal insufficiency\"}]"},{"user":"ALD is due to mutation of a gene located in Xq28 that encodes a peroxisomal transporter protein of unknown function.The most common phenotype of ALD is the cerebral form (45%) that develops in boys between 5-12 yr. Adrenomyeloneuropathy (AMN) involves the spinal cord and peripheral nerves in young adults (35%).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"ALD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ALD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Adrenomyeloneuropathy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"AMN\"}]"},{"user":"Adrenal insufficiency (Addisons disease) is frequently associated with AMN or cerebral ALD and may remain the only clinical expression of ALD (8% of cases).The prevalence of ALD among adults with Addisons disease remains unknown.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"Adrenal insufficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Addisons disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"AMN\"}, {\"category\": \"SpecificDisease\", \"entity\": \"cerebral ALD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ALD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ALD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Addisons disease\"}]"},{"user":"To evaluate this prevalence, we performed biochemical analysis of very long chain fatty acids in 14 male patients (age ranging from 12-45 yr at diagnosis) previously diagnosed as having primary idiopathic adrenocortical insufficiency.In 5 of 14 patients (35%), elevated plasma concentrations of very long chain fatty acids were detected.None of these patients had adrenocortical antibodies.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"adrenocortical insufficiency\"}]"},{"user":"By electrophysiological tests and magnetic resonance imaging it was determined that two patients had cerebral ALD, one had adrenomyeloneuropathy with cerebral involvement, and two had preclinical AMN.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"cerebral ALD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"adrenomyeloneuropathy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"AMN\"}]"},{"user":"Our data support the hypothesis that ALD is a frequent cause of idiopathic Addisons disease\nLow incidence of BRCA2 mutations in breast carcinoma and other cancers.Inherited mutant alleles of familial tumour suppressor genes predispose individuals to particular types of cancer.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"ALD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Addisons disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast carcinoma\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancers\"}, {\"category\": \"Modifier\", \"entity\": \"tumour\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancer\"}]"},{"user":"In addition to an involvement in inherited susceptibility to cancer, these tumour suppressor genes are targets for somatic mutations in sporadic cancers of the same type found in the familial forms.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"cancer\"}, {\"category\": \"Modifier\", \"entity\": \"tumour\"}, {\"category\": \"DiseaseClass\", \"entity\": \"sporadic cancers\"}]"},{"user":"An exception is BRCA1, which contributes to a significant fraction of familial breast and ovarian cancer, but undergoes mutation at very low rates in sporadic breast and ovarian cancers.This finding suggests that other genes may be the principal targets for somatic mutation in breast carcinoma.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"familial breast and ovarian cancer\"}, {\"category\": \"CompositeMention\", \"entity\": \"sporadic breast and ovarian cancers\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast carcinoma\"}]"},{"user":"A second, recently identified familial breast cancer gene, BRCA2 (refs 5-8), accounts for a proportion of breast cancer roughly equal to BRCA1.Like BRCA1, BRCA2 behaves as a dominantly inherited tumour suppressor gene.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"familial breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"Modifier\", \"entity\": \"tumour\"}]"},{"user":"Individuals who inherit one mutant allele are at increased risk for breast cancer, and the tumours they develop lose the wild-type allele by heterozygous deletion.The BRCA2 coding sequence is huge, composed of 26 exons that span 10, 443 bp.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tumours\"}]"},{"user":"Here we investigate the rate of BRCA2 mutation in sporadic breast cancers and in a set of cell lines that represent twelve other tumour types.Surprisingly, mutations in BRCA2 are infrequent in cancers including breast carcinoma.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"sporadic breast cancers\"}, {\"category\": \"Modifier\", \"entity\": \"tumour\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancers\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast carcinoma\"}]"},{"user":"However, a probable germline mutation in a pancreatic tumour cell line suggests a role for BRCA2 in susceptibility to pancreatic cancer\nType III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development.Type III collagen is a fibrillar forming collagen comprising three alpha1 (III) chains and is expressed in early embryos and throughout embryogenesis.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"pancreatic tumour\"}, {\"category\": \"SpecificDisease\", \"entity\": \"pancreatic cancer\"}]"},{"user":"In the adult, type III collagen is a major component of the extracellular matrix in a variety of internal organs and skin.Mutations in the COL3A1 gene have been implicated as a cause of type IV Ehlers-Danlos syndrome, a disease leading to aortic rupture in early adult life.To directly study the role of Col3a1 in development and disease, we have inactivated the Col3a1 gene in embryonic stem cells by homologous recombination.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"type IV Ehlers-Danlos syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"aortic rupture\"}]"},{"user":"The mutated allele was transmitted through the mouse germ line and homozygous mutant animals were derived from heterozygous intercrosses.About 10% of the homozygous mutant animals survived to adulthood but have a much shorter life span compared with wild-type mice.","assistant":"]"},{"user":"The major cause of death of mutant mice was rupture of the major blood vessels, similar to patients with type IV Ehlers-Danlos syndrome\nThe incidence of PAX6 mutation in patients with simple aniridia: an evaluation of mutation detection in 12 cases.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"type IV Ehlers-Danlos syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"aniridia\"}]"},{"user":"Twelve aniridia patients, five with a family history and seven presumed to be sporadic, were exhaustively screened in order to test what proportion of people with aniridia\nGermline mutations in the 3' part of APC exon 15 do not result in truncated proteins and are associated with attenuated adenomatous polyposis coli.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"aniridia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"aniridia\"}, {\"category\": \"Modifier\", \"entity\": \"APC\"}, {\"category\": \"SpecificDisease\", \"entity\": \"adenomatous polyposis coli\"}]"},{"user":"Familial adenomatous polyposis (FAP) is an inherited predisposition to colorectal cancer characterized by the development of numerous adenomatous polyps predominantly in the colorectal region.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Familial adenomatous polyposis\"}, {\"category\": \"SpecificDisease\", \"entity\": \"FAP\"}, {\"category\": \"SpecificDisease\", \"entity\": \"colorectal cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"adenomatous polyps\"}]"},{"user":"Germline mutations in the adenomatous polyposis coli (APC) gene are responsible for most cases of FAP.Mutations at the 5 end of APC are known to be associated with a relatively mild form of the disease, called attenuated adenomatous polyposis coli (AAPC).","assistant":"[{\"category\": \"Modifier\", \"entity\": \"adenomatous polyposis coli\"}, {\"category\": \"Modifier\", \"entity\": \"APC\"}, {\"category\": \"SpecificDisease\", \"entity\": \"FAP\"}, {\"category\": \"SpecificDisease\", \"entity\": \"APC\"}, {\"category\": \"SpecificDisease\", \"entity\": \"attenuated adenomatous polyposis coli\"}, {\"category\": \"SpecificDisease\", \"entity\": \"AAPC\"}]"},{"user":"We identified a frameshift mutation in the 3 part of exon 15, resulting in a stop codon at 1862, in a large Dutch kindred with AAPC.Western blot analysis of lymphoblastoid cell lines derived from affected family members from this kindred, as well as from a previously reported Swiss family carrying a frameshift mutation at codon 1987 and displaying a similar attenuated phenotype, showed only the wild-type APC protein.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"AAPC\"}, {\"category\": \"Modifier\", \"entity\": \"APC\"}]"},{"user":"Our study indicates that chain-terminating mutations located in the 3 part of APC do not result in detectable truncated polypeptides and we hypothesize that this is likely to be the basis for the observed AAPC\nAbsence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"APC\"}, {\"category\": \"Modifier\", \"entity\": \"AAPC\"}, {\"category\": \"Modifier\", \"entity\": \"Huntington disease\"}]"},{"user":"The mutation underlying Huntington disease (HD) is CAG expansion in the first exon of the HD gene.In order to investigate the role of CAG expansion in the pathogenesis of HD, we have produced transgenic mice containing the full length human HD cDNA with 44 CAG repeats.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Huntington disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HD\"}, {\"category\": \"Modifier\", \"entity\": \"HD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HD\"}, {\"category\": \"Modifier\", \"entity\": \"HD\"}]"},{"user":"By 1 year, these mice have no behavioral abnormalities and morphometric analysis at 6 (one animal) and 9 (two animals) months age revealed no changes.Despite high levels of mRNA expression, there was no evidence of the HD gene product in any of these transgenic mice.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"behavioral abnormalities\"}, {\"category\": \"Modifier\", \"entity\": \"HD\"}]"},{"user":"In vitro transfection studies indicated that the inclusion of 120 bp of the 5 UTR in the cDNA construct and the presence of a frameshift mutation at nucleotide 2349 prevented expression of the HD cDNA.These findings suggest that the pathogenesis of HD is not mediated through DNA-protein interaction and that presence of the RNA transcript with an expanded CAG repeat is insufficient to cause the disease.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"HD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HD\"}]"},{"user":"Rather, translation of the CAG is crucial for the pathogenesis of HD\nDetection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis.The ability to scan a large gene rapidly and accurately for all possible heterozygous mutations in large numbers of patient samples will be critical for the future of medicine.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"HD\"}]"},{"user":"We have designed high-density arrays consisting of over 96, 600 oligonucleotides 20-nucleotides (nt) in length to screen for a wide range of heterozygous mutations in the 3.45-kilobases (kb) exon 11 of the hereditary breast and ovarian cancer\nColchicine in breast milk of patients with familial Mediterranean fever.OBJECTIVE.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"hereditary breast and ovarian cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"familial Mediterranean fever\"}]"},{"user":"To clarify whether colchicine is excreted in breast milk, and to compare its concentrations in the serum and breast milk of lactating women who have familial Mediterranean fever (FMF).METHODS.Using a specific radioimmunoassay, we determined colchicine concentrations in the serum and breast milk of 4 patients at various time points, following oral administration of the drug.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"familial Mediterranean fever\"}, {\"category\": \"SpecificDisease\", \"entity\": \"FMF\"}]"},{"user":"The study evaluated 4 patients with FMF who had been taking colchicine on a long-term basis.RESULTS.Colchicine was found to be excreted in breast milk.Its levels ranged between 1.9 and 8.6 ng\/ml, which were similar to those found in the serum (parallel concentration time curves).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"FMF\"}]"},{"user":"However, there appeared to be a considerable variation in colchicine milk concentration among the different patients, which might be related to individual breast milk composition and, possibly, to other nutritional or metabolic factors.CONCLUSION.The extensive peripheral tissue binding and relatively low concentration of colchicine in breast milk suggests that the amount ingested by the infant is small.","assistant":"]"},{"user":"Furthermore, based on our clinical experience, nursing appears to be safe for lactating women with FMF\nThe human complement C9 gene: identification of two mutations causing deficiency and revision of the gene structure.The ninth component of human complement (C9) is the last of the terminal complement components creating the membrane attack complex.C9 is a single-chain serum protein that is encoded by a gene located on chromosome 5p.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"FMF\"}]"},{"user":"Deficiency of terminal complement components is generally associated with recurrent neisseria infections.We studied a previously described Swiss family with inherited C9 deficiency.To identify the genetic basis of C9 deficiency, we developed an approach using exon-specific PCR and direct DNA sequencing.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Deficiency of terminal complement components\"}, {\"category\": \"SpecificDisease\", \"entity\": \"neisseria infections\"}, {\"category\": \"SpecificDisease\", \"entity\": \"inherited C9 deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"C9 deficiency\"}]"},{"user":"As a cause of C9 deficiency , we found two different point mutations, both generating TGA stop codons in the coding sequence.One mutation, a C to A exchange, was detected in exon 2 at cDNA position 166, the other, a C to T exchange, was located in exon 4 (cDNA position 464).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"C9 deficiency\"}]"},{"user":"In family studies of three first-degree relatives with heterozygous C9 deficiency\nMolecular heterogeneity of classical and Duarte galactosemia: mutation analysis by denaturing gradient gel electrophoresis.Classical galactosemia is caused by one common missense mutation (Q188R) and by several rare mutations in the galactose-1-phosphate uridyltransferase (GALT) gene.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"C9 deficiency\"}, {\"category\": \"CompositeMention\", \"entity\": \"classical and Duarte galactosemia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Classical galactosemia\"}]"},{"user":"The most common variant of GALT, the Duarte variant, occurs as two types, Duarte-1 (D-1) and Duarte-2 (D-2), both of which carry the sequence change N314D.D-1 increases, whereas D-2 decreases GALT activity.","assistant":"]"},{"user":"To study the molecular genetics of classical and Duarte galactosemia, we analyzed the GALT mutations in 30 families with classical galactosemia, in 10 families with the D-2 variant and in 3 individuals carrying the D-1 allele by denaturing gradient gel electrophoresis (DGGE).DGGE detected 59 of the 60 classical galactosemia alleles.Q188R accounted for 60%, K285N accounted for 28% of these alleles.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"classical and Duarte galactosemia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"classical galactosemia\"}, {\"category\": \"Modifier\", \"entity\": \"galactosemia\"}]"},{"user":"Eight novel candidate galactosemia mutations were found.On all D-2 alleles N314D occurred in cis with two intronic sequence changes, on the D-1 alleles in cis with a neutral mutation in exon 7.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"galactosemia\"}]"},{"user":"We conclude that the mutations causing galactosemia are highly heterogeneous and that K285N is a second common galactosemia\nNonsense mutation in exon 3 of the proteolipid protein gene (PLP) in a family with an unusual form of Pelizaeus-Merzbacher disease.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"galactosemia\"}, {\"category\": \"Modifier\", \"entity\": \"galactosemia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Pelizaeus-Merzbacher disease\"}]"},{"user":"We report a G-- > A transition at nucleotide 431 of the proteolipid protein gene (PLP) results in a nonsense codon in a family with an unusual form of Pelizaeus-Merzbacher disease (PMD).The mutation, which creates a second AluI restriction site, results in a nonsense mutation in PLP.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Pelizaeus-Merzbacher disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"PMD\"}]"},{"user":"The clinical picture resembles somewhat that of X-linked spastic paraplegia (SPG).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"X-linked spastic paraplegia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"SPG\"}]"},{"user":"It differs from this and both the classical and connatal forms of PMD in that it is relatively mild in form, onset is delayed beyond age 2 years, nystagmus is absent, tremors are prominent, mental retardation is not severe, some patients show dementia or personality disorders, the disease is progressive rather than static in some, and several females show signs of disease.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"PMD\"}, {\"category\": \"DiseaseClass\", \"entity\": \"nystagmus\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tremors\"}, {\"category\": \"DiseaseClass\", \"entity\": \"mental retardation\"}, {\"category\": \"DiseaseClass\", \"entity\": \"dementia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"personality disorders\"}]"},{"user":"The nonsense mutation, which is in exon 3B, should block the synthesis of normal PLP but spare DM20, the isoform whose persistence has been associated with mild forms of PLP-associated disease\nThe hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.Pediatric alveolar rhabdomyosarcoma\nA clinical overview of WT1 gene mutations.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"PLP-associated disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"alveolar rhabdomyosarcoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Pediatric alveolar rhabdomyosarcoma\"}]"},{"user":"Mutations in the WT1 gene were anticipated to explain the genetic basis of the childhood kidney cancer, Wilms tumour (WT).Six years on, we review 100 reports of intragenic WT1 mutations and examine the accompanying clinical phenotypes.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"kidney cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Wilms tumour\"}, {\"category\": \"SpecificDisease\", \"entity\": \"WT\"}]"},{"user":"While only 5% of sporadic Wilms tumours have intragenic WT1 mutations, > 90% of patients with the Denys-Drash syndrome (renal nephropathy, gonadal anomaly, predisposition to WT) carry constitutional intragenic WT1 mutations.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"sporadic Wilms tumours\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Denys-Drash syndrome\"}, {\"category\": \"DiseaseClass\", \"entity\": \"renal nephropathy\"}, {\"category\": \"DiseaseClass\", \"entity\": \"gonadal anomaly\"}, {\"category\": \"DiseaseClass\", \"entity\": \"predisposition to WT\"}]"},{"user":"WT1 mutations have also been reported in juvenile granulosa cell tumour, non-asbestos related mesothelioma, desmoplastic small round cell tumour and, most recently, acute myeloid leukemia\nDual roles of ATM in the cellular response to radiation and in cell growth control.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"juvenile granulosa cell tumour\"}, {\"category\": \"SpecificDisease\", \"entity\": \"non-asbestos related mesothelioma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"desmoplastic small round cell tumour\"}, {\"category\": \"SpecificDisease\", \"entity\": \"acute myeloid leukemia\"}]"},{"user":"The gene mutated in ataxia-telangiectasia (AT) patients, denoted ATM, encodes a putative protein or lipid kinase.To elucidate the functions of ATM, we disrupted the mouse ATM gene through homologous recombination in mice.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"Modifier\", \"entity\": \"AT\"}]"},{"user":"Consistent with cellular defects of AT patients, the ATM-\/- cells are hypersensitive to gamma-irradiation and defective in cell-cycle arrest following radiation, correlating with a defective up-regulation of p53.In addition, ATM-\/- mouse thymocytes are more resistant to apoptosis induced by gamma-irradiation than normal thymocytes.ATM-\/- fibroblasts are inefficient in G1 to S-phase progression following serum stimulation and senesce after only a few passages in culture.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"AT\"}]"},{"user":"They have an increased constitutive level of p21CP1\/WAF1.The ATM protein is therefore critical both for cellular responses to ionizing radiation and for normal cell-cycle progression.","assistant":"]"},{"user":"ATM +\/- fibroblasts and thymocytes showed intermediately defective responses to irradiation but no growth defect, suggesting that the increased cancer risk of AT\nIdentification and expression of eight novel mutations among non-Jewish patients with Canavan disease.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"cancer\"}, {\"category\": \"Modifier\", \"entity\": \"AT\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Canavan disease\"}]"},{"user":"Canavan disease is inherited as an autosomal recessive trait that is caused by the deficiency of aspartoacylase (ASPA).The majority of patients with Canavan disease are from an Ashkenazi Jewish background.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Canavan disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"deficiency of aspartoacylase\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Canavan disease\"}]"},{"user":"Mutations in ASPA that lead to loss of enzymatic activity have been identified, and E285A and Y231X are the two predominant mutations that account for 97% of the mutant chromosomes in Ashkenazi Jewish patients.The current study was aimed at finding the molecular basis of Canavan disease in 25 independent patients of non-Jewish background.Eight novel and three previously characterized mutations accounted for 80% (40\/50) of mutant chromosomes.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Canavan disease\"}]"},{"user":"The A305E missense mutation accounted for 48% (24\/50) of mutant chromosomes in patients of western European descent, while the two predominant Jewish mutations each accounted for a single mutant chromosome.The eight novel mutations identified included 1- and 4-bp deletions (32 deltaT and 876 deltaAGAA, respectively) and I16T, G27R, D114E, G123E, C152Y, and R168C missense mutations.","assistant":"]"},{"user":"The homozygous 32 deltaT deletion was identified in the only known patient of African-American origin with Canavan disease.The heterozygosity for 876 deltaAGAA mutation was identified in three independent patients from England.Six single-base changes leading to missense mutations were identified in patients from Turkey (D114E, R168C), The Netherlands (I16T), Germany (G27R), Ireland (C152Y), and Canada (G123E).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Canavan disease\"}]"},{"user":"A PCR-based protocol is described that was used to introduce mutations in wild-type cDNA.In vitro expression of mutant cDNA clones demonstrated that all of these mutations led to a deficiency of ASPA and should therefore result in Canavan disease\nBRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"deficiency of ASPA\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Canavan disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"BACKGROUND  To define the incidence of BRCA1 mutations among patients seen in clinics that evaluate the risk of breast cancer, we analyzed DNA samples from women seen in this setting and constructed probability tables to provide estimates of the likelihood of finding a BRCA1 mutation in individual families.METHODS  Clinical information, family histories, and blood for DNA analysis were obtained from 263 women with breast cancer.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"Conformation-sensitive gel electrophoresis and DNA sequencing were used to identify BRCA1 mutations.RESULTS  BRCA1 mutations were identified in 16 percent of women with a family history of breast cancer.Only 7 percent of women from families with a history of breast cancer but not ovarian cancer had BRCA1 mutations.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ovarian cancer\"}]"},{"user":"The rates were higher among women from families with a history of both breast and ovarian cancer.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"breast and ovarian cancer\"}]"},{"user":"Among family members, an average age of less than 55 years at the diagnosis of breast cancer, the presence of ovarian cancer, the presence of breast and ovarian cancer in the same woman, and Ashkenazi Jewish ancestry were all associated with an increased risk of detecting a BRCA1 mutation.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ovarian cancer\"}, {\"category\": \"CompositeMention\", \"entity\": \"breast and ovarian cancer\"}]"},{"user":"No association was found between the presence of bilateral breast cancer or the number of breast cancers in a family and the detection of a BRCA1 mutation, or between the position of the mutation in the BRCA1 gene and the presence of ovarian cancer in a family.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancers\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ovarian cancer\"}]"},{"user":"CONCLUSIONS  Among women with breast cancer\nThe von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"Modifier\", \"entity\": \"von Hippel-Lindau tumor\"}]"},{"user":"The von Hippel-Lindau tumor suppressor gene (VHL) has a critical role in the pathogenesis of clear-cell renal cell carcinoma (RCC), as VHL mutations have been found in both von Hippel-Lindau disease-associated and sporadic RCCs.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"von Hippel-Lindau tumor\"}, {\"category\": \"SpecificDisease\", \"entity\": \"clear-cell renal cell carcinoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"RCC\"}, {\"category\": \"CompositeMention\", \"entity\": \"von Hippel-Lindau disease-associated and sporadic RCCs\"}]"},{"user":"Recent studies suggest that vascular endothelial growth factor (VEGF) mRNA is upregulated in RCC- and von Hippel-Lindau disease-associated tumors.We have therefore assessed the effect of the VHL gene product on VEGF expression.VEGF promoter-luciferase constructs were transiently cotransfected with a wild-type VHL (wt-VHL) vector in several cell lines, including 293 embryonic kidney and RCC cell lines.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"RCC- and von Hippel-Lindau disease-associated tumors\"}, {\"category\": \"Modifier\", \"entity\": \"RCC\"}]"},{"user":"wt-VHL protein inhibited VEGF promoter activity in a dose-dependent manner up to 5- to 10-fold.Deletion analysis defined a 144-bp region of the VEGF promoter necessary for VHL repression.This VHL-responsive element is GC rich and specifically binds the transcription factor Sp1 in crude nuclear extracts.In Drosophila cells, cotransfected VHL represses Sp1-mediated activation but not basal activity of the VEGF promoter.","assistant":"]"},{"user":"We next demonstrated in coimmunoprecipitates that VHL and Sp1 were part of the same complex and, by using a glutathione-S-transferase-VHL fusion protein and purified Sp1, that VHL and Sp1 directly interact.Furthermore, endogenous VEGF mRNA levels were suppressed in permanent RCC cell lines expressing wt-VHL, and nuclear run-on studies indicated that VHL regulation of VEGF occurs at least partly at the transcriptional level.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"RCC\"}]"},{"user":"These observations support a new mechanism for VHL-mediated transcriptional repression via a direct inhibitory action on Sp1 and suggest that loss of Sp1 inhibition may be important in the pathogenesis of von Hippel-Lindau disease and RCC\nGermline mutations in the RB1 gene in patients with hereditary retinoblastoma.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"von Hippel-Lindau disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"RCC\"}, {\"category\": \"SpecificDisease\", \"entity\": \"hereditary retinoblastoma\"}]"},{"user":"We have analyzed the 27 exons and the promoter region of the RB1 gene in familial or sporadic bilateral retinoblastoma\nDeletion of small nuclear ribonucleoprotein polypeptide N (SNRPN) in Prader-Willi syndrome detected by fluorescence in situ hybridization: two sibs with the typical phenotype without a cytogenetic deletion in chromosome 15q.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"familial or sporadic bilateral retinoblastoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Prader-Willi syndrome\"}]"},{"user":"The small nuclear ribonucleoprotein polypeptide N (SNRPN) gene is regarded as one of the candidates for Prader-Willi syndrome (PWS).We describe two sibs with typical PWS presenting deletion of SNRPN detected by fluorescence in situ hybridization (FISH).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Prader-Willi syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"PWS\"}, {\"category\": \"SpecificDisease\", \"entity\": \"PWS\"}]"},{"user":"Neither a cytogenetically detectable 15q12 deletion nor a deletion for the D15S11, D15S10, and GABRB3 cosmid probes were found in either patient.This implies a smaller deletion limited to the PWS critical region.FISH with a SNRPN probe will permit analysis of PWS\nThe mouse homolog of the Wiskott-Aldrich syndrome protein (WASP) gene is highly conserved and maps near the scurfy (sf) mutation on the X chromosome.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"PWS\"}, {\"category\": \"Modifier\", \"entity\": \"PWS\"}, {\"category\": \"Modifier\", \"entity\": \"Wiskott-Aldrich syndrome\"}]"},{"user":"The mouse WASP gene, the homolog of the gene mutated in Wiskott-Aldrich syndrome, has been isolated and sequenced.the predicted amino acid sequence is 86% identical to the human WASP sequence.A distinct feature of the mouse gene is an expanded polymorphic GGA trinucleotide repeat that codes for polyglycine and varies from 15 to 17 triplets in different Mus musculus strains.The genomic structure of the mouse WASP gene is expressed as an approximately 2.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Wiskott-Aldrich syndrome\"}]"},{"user":"4-kb mRNA in thymus and spleen.Chromosomal mapping in an interspecific M. Musculus\/M.spretus backcross placed the Wasp locus near the centromere of the mouse X chromosome, inseparable from Gata1, Tcfe3, and scurfy (sf).","assistant":"]"},{"user":"This localization makes Wasp a candidate for involvement in scurfy, a T cell-mediated fatal lymphoreticular disease of mice that has previously been proposed as a mouse homolog of Wiskott-Aldrich syndrome\nAn animal model for Norrie disease (ND): gene targeting of the mouse ND gene.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"fatal lymphoreticular disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Wiskott-Aldrich syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Norrie disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ND\"}, {\"category\": \"Modifier\", \"entity\": \"ND\"}]"},{"user":"In order to elucidate the cellular and molecular processes which are involved in Norrie disease (ND), we have used gene targeting technology to generate ND mutant mice.The murine homologue of the ND gene was cloned and shown to encode a polypeptide that shares 94% of the amino acid sequence with its human counterpart.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Norrie disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ND\"}, {\"category\": \"Modifier\", \"entity\": \"ND\"}, {\"category\": \"Modifier\", \"entity\": \"ND\"}]"},{"user":"RNA in situ hybridization revealed expression in retina, brain and the olfactory bulb and epithelium of 2 week old mice.Hemizygous mice carrying a replacement mutation in exon 2 of the ND gene developed retrolental structures in the vitreous body and showed an overall disorganization of the retinal ganglion cell layer.The outer plexiform layer disappears occasionally, resulting in a juxtaposed inner and outer nuclear layer.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"ND\"}]"},{"user":"At the same regions, the outer segments of the photoreceptor cell layer are no longer present.","assistant":"]"},{"user":"These ocular findings are consistent with observations in ND patients and the generated mouse line provides a faithful model for study of early pathogenic events in this severe X-linked recessive neurological disorder\nPhenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"ND\"}, {\"category\": \"DiseaseClass\", \"entity\": \"X-linked recessive neurological disorder\"}, {\"category\": \"Modifier\", \"entity\": \"Huntington disease\"}, {\"category\": \"Modifier\", \"entity\": \"HD\"}, {\"category\": \"Modifier\", \"entity\": \"HD\"}]"},{"user":"Abnormal CAG expansions in the IT-15 gene are associated with Huntington disease (HD).In the diagnostic setting it is necessary to define the limits of the CAG size ranges on normal and HD-associated chromosomes.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Huntington disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HD\"}, {\"category\": \"Modifier\", \"entity\": \"HD\"}]"},{"user":"Most large analyses that defined the limits of the normal and pathological size ranges employed PCR assays, which included the CAG repeats and a CCG repeat tract that was thought to be invariant.Many of these experiments found an overlap between the normal and disease size ranges.Subsequent findings that the CCG repeats vary by 8 trinucleotide lengths suggested that the limits of the normal and disease size ranges should be reevaluated with assays that exclude the CCG polymorphism.","assistant":"]"},{"user":"Since patients with between 30 and 40 repeats are rare, a consortium was assembled to collect such individuals.All 178 samples were reanalyzed in Cambridge by using assays specific for the CAG repeats.We have optimized methods for reliable sizing of CAG repeats and show cases that demonstrate the dangers of using PCR assays that include both the CAG and CCG polymorphisms.Seven HD patients had 36 repeats, which confirms that this allele is associated with disease.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"HD\"}]"},{"user":"Individuals without apparent symptoms or signs of HD were found at 36 repeats (aged 74, 78, 79, and 87 years), 37 repeats (aged 69 years), 38 repeats (aged 69 and 90 years), and 39 repeats (aged 67, 90, and 95 years).The detailed case histories of an exceptional case from this series will be presented  a 95-year-old man with 39 repeats who did not have classical features of HD.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"HD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HD\"}]"},{"user":"The apparently healthy survival into old age of some individuals with 36-39 repeats suggests that the HD\nHPRT-APRT-deficient mice are not a model for lesch-nyhan syndrome.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"HD\"}, {\"category\": \"Modifier\", \"entity\": \"HPRT-APRT-deficient\"}, {\"category\": \"SpecificDisease\", \"entity\": \"lesch-nyhan syndrome\"}]"},{"user":"Complete hypoxanthine-guanine phosphoribosyl-transferase (HPRT) deficiency in humans results in the Lesch-Nyhan syndrome which is characterized, among other features, by compulsive self-injurious behavior.HPRT-deficient mice generated using mouse embryonic stem cells exhibit none of the behavioral symptoms associated with the Lesch-Nyhan syndrome.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Complete hypoxanthine-guanine phosphoribosyl-transferase (HPRT) deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Lesch-Nyhan syndrome\"}, {\"category\": \"Modifier\", \"entity\": \"HPRT-deficient\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Lesch-Nyhan syndrome\"}]"},{"user":"Administration of drugs that inhibit adenine phosphoribosyltransferase (APRT) in HPRT-deficient mice has produced the suggestion that deficiency of APRT in combination with HPRT-deficiency in mice may lead to self-mutilation behavior [C. L. Wu and D. W. Melton (1993) Nature Genet.3, 235-240].To test this proposition, we bred HPRT-APRT-deficient mice.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"HPRT-deficient\"}, {\"category\": \"SpecificDisease\", \"entity\": \"deficiency of APRT\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HPRT-deficiency\"}, {\"category\": \"Modifier\", \"entity\": \"HPRT-APRT-deficient\"}]"},{"user":"Although the doubly-deficient mice excrete adenine and its highly insoluble derivative, 2, 8-dihydroxyadenine, which are also associated with human APRT deficiency, additional abnormalities or any self-injurious behavior were not detected.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"APRT deficiency\"}]"},{"user":"Thus, APRT-HPRT-deficient mice, which are devoid of any purine salvage pathways, show no novel phenotype and are not a model for the behavioral abnormalities associated with the Lesch-Nyhan syndrome\nMice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"APRT-HPRT-deficient\"}, {\"category\": \"DiseaseClass\", \"entity\": \"behavioral abnormalities\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Lesch-Nyhan syndrome\"}, {\"category\": \"Modifier\", \"entity\": \"myotonic dystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"myopathy\"}]"},{"user":"Myotonic dystrophy (DM) is an autosomal dominant disorder resulting from the expansion of a CTG repeat in the 3 untranslated region of a putative protein kinase (DMPK).To elucidate the role of DMPK in DM pathogenesis we have developed Dmpk deficient (Dmpk-\/-) mice.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Myotonic dystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DM\"}, {\"category\": \"DiseaseClass\", \"entity\": \"autosomal dominant disorder\"}, {\"category\": \"Modifier\", \"entity\": \"DM\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Dmpk deficient\"}]"},{"user":"Dmpk-\/-mice develop a late-onset, progressive skeletal myopathy that shares some pathological features with DM.Muscles from mature mice show variation in fibre size, increased fibre degeneration and fibrosis.Adult Dmpk-\/-mice show ultrastructural changes in muscle and a 50% decrease in force generation compared to young mice.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"progressive skeletal myopathy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DM\"}, {\"category\": \"SpecificDisease\", \"entity\": \"fibre degeneration\"}, {\"category\": \"SpecificDisease\", \"entity\": \"fibrosis\"}]"},{"user":"Our results indicate that DMPK may be necessary for the maintenance of skeletal muscle structure and function and suggest that a decrease in DMPK levels may contribute to DM\nRapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis.UKCCCR Familial Ovarian Cancer Study Group.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"DM\"}, {\"category\": \"Modifier\", \"entity\": \"Ovarian Cancer\"}]"},{"user":"Germ-line mutations of the BRCA1 gene are responsible for a substantial proportion of families with multiple cases of early-onset breast and\/or ovarian cancer.Since the isolation of BRCA1 last year, > 65 distinct mutations scattered throughout the coding region have been detected, making analysis of the gene time consuming and technically challenging.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"breast and\/or ovarian cancer\"}]"},{"user":"We have developed a multiplex heteroduplex analysis that is designed to analyze one-quarter of the coding sequence in a single-step screening procedure and that will detect approximately 50% of all BRCA1 mutations so far reported in breast\/ovarian cancer families.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"breast\/ovarian cancer\"}]"},{"user":"We have used this technique to analyze BRCA1 in 162 families with a history of breast and\/or ovarian cancer\nLPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family.A major cytogenetic subgroup of lipomas is characterized by recurrent chromosome aberrations, mainly translocations, that involve chromosome segment 12q13-q15.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"breast and\/or ovarian cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"lipomas\"}, {\"category\": \"DiseaseClass\", \"entity\": \"lipomas\"}]"},{"user":"Multiple chromosomes have been found as the translocation partners of chromosome 12 but 3q27-q28 is preferentially involved.In previous studies, it has been shown that the high mobility group (HMG) protein gene HMGIC at 12q15 is consistently rearranged as a consequence of these translocations.Here, we report the identification and characterization of the chromosome 3-derived translocation partner gene, which we have designated LPP (lipoma preferred partner gene).","assistant":"[{\"category\": \"Modifier\", \"entity\": \"lipoma\"}]"},{"user":"Using 3-RACE analysis of HMGIC fusion transcripts in lipoma cell line Li-501\/SV40, ectopic genetic sequences were obtained, which by CASH (chromosome assignment using somatic cell hybrids) and FISH (fluorescence in situ hybridization) analysis were found to originate from chromosome segment 3q27-q28.In Northern blot analysis, an mRNA of over 10 kb was detected by these ectopic sequences in a variety of human tissues but not in brain and peripheral blood leukocytes.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"lipoma\"}]"},{"user":"Upon partial cDNA cloning, features of the genetic organization of LPP were established.The gene was found to span a genomic region of over 400 kb.Nucleotide sequence analysis of a composite cDNA of LPP revealed an open reading frame of 1836 nucleotides encoding a proline-rich protein containing a leucine-zipper motif in its amino-terminal region and three LIM domains in its carboxy-terminal region.","assistant":"]"},{"user":"The LPP-encoded protein should be classified as a novel member of the group 3 proteins of the LIM protein gene family.Using reverse transcriptase combined with polymerase chain reactions in the analysis of a number of lipoma cell lines and primary lipomas\nExon-intron structure of the human neuronal nicotinic acetylcholine receptor alpha 4 subunit (CHRNA4).","assistant":"[{\"category\": \"Modifier\", \"entity\": \"lipoma\"}, {\"category\": \"DiseaseClass\", \"entity\": \"primary lipomas\"}]"},{"user":"The human neuronal nicotinic acetylcholine receptor alpha 4 subunit gene (CHRNA4) is located in the candidate region for three different phenotypes  benign familial neonatal convulsions, autosomal dominant nocturnal frontal lobe epilepsy, and low-voltage EEG.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"benign familial neonatal convulsions\"}, {\"category\": \"SpecificDisease\", \"entity\": \"autosomal dominant nocturnal frontal lobe epilepsy\"}]"},{"user":"Recently, a missense mutation in transmembrane domain 2 of CHRNA4 was found to be associated with autosomal dominant nocturnal frontal lobe epilepsy in one extended pedigree.We have determined the genomic organization of CHRNA4, which consists of six exons distributed over approximately 17 kb of genomic DNA.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"autosomal dominant nocturnal frontal lobe epilepsy\"}]"},{"user":"The nucleotide sequence obtained from the genomic regions adjacent to the exon boundaries enabled us to develop a set of primer pairs for PCR amplification of the complete coding region.","assistant":"]"},{"user":"The sequence analysis provides the basis for a comprehensive mutation screening of CHRNA4 in the above-mentioned phenotypes and possibly in other types of idiopathic epilepsies\nA novel homeodomain-encoding gene is associated with a large CpG island interrupted by the myotonic dystrophy unstable (CTG)n repeat.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"idiopathic epilepsies\"}, {\"category\": \"Modifier\", \"entity\": \"myotonic dystrophy\"}]"},{"user":"Myotonic dystrophy (DM) is associated with a (CTG) n trinucleotide repeat expansion in the 3-untranslated region of a protein kinase-encoding gene, DMPK, which maps to chromosome 19q13.3.Characterisation of the expression of this gene in patient tissues has thus far generated conflicting data on alterations in the steady state levels of DMPK mRNA, and on the final DMPK protein levels in the presence of the expansion.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Myotonic dystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DM\"}]"},{"user":"The DM region of chromosome 19 is gene rich, and it is possible that the repeat expansion may lead to dysfunction of a number of transcription units in the vicinity, perhaps as a consequence of chromatin disruption.We have searched for genes associated with a CpG island at the 3 end of DMPK.Sequencing of this region shows that the island extends over 3.5 kb and is interrupted by the (CTG) n repeat.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"DM\"}]"},{"user":"Comparison of genomic sequences downstream (centromeric) of the repeat in human and mouse identified regions of significant homology.These correspond to exons of a gene predicted to encode a homeodomain protein.RT-PCR analysis shows that this gene, which we have called DM\nMissense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"DM\"}, {\"category\": \"SpecificDisease\", \"entity\": \"autoimmune lymphoproliferative syndrome\"}]"},{"user":"Programmed cell death (or apoptosis) is a physiological process essential to the normal development and homeostatic maintenance of the immune system.The Fas\/Apo-1 receptor plays a crucial role in the regulation of apoptosis, as demonstrated by lymphoproliferation in MRL-lpr\/lpr mice and by the recently described autoimmune lymphoproliferative syndrome (ALPS) in humans, both of which are due to mutations in the Fas gene.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"autoimmune lymphoproliferative syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ALPS\"}]"},{"user":"We describe a novel family with ALPS in which three affected siblings carry two distinct missense mutations on both the Fas gene alleles and show lack of Fas-induced apoptosis.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"ALPS\"}]"},{"user":"The children share common clinical features including splenomegaly and lymphadenopathy, but only one developed severe autoimmune manifestations\nCommon BRCA1 variants and susceptibility to breast and ovarian cancer in the general population.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"splenomegaly\"}, {\"category\": \"DiseaseClass\", \"entity\": \"lymphadenopathy\"}, {\"category\": \"DiseaseClass\", \"entity\": \"autoimmune manifestations\"}, {\"category\": \"CompositeMention\", \"entity\": \"breast and ovarian cancer\"}]"},{"user":"Most multiple case families of young onset breast cancer and ovarian cancer are thought to be due to highly penetrant mutations in the predisposing genes BRCA1 and BRCA2.However, these mutations are uncommon in the population and they probably account for only a few percent of all breast cancer incidence.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ovarian cancer\"}, {\"category\": \"Modifier\", \"entity\": \"breast cancer\"}]"},{"user":"A much larger fraction of breast cancer might, in principle, be due to common variants which confer more modest individual risks.There are several common polymorphisms in the BRCA1 gene which generate amino acid substitutions.We have examined the frequency of four of these polymorphisms  Gln356Arg, Pro871Leu, Glu1038Gly and Ser1613Gly in large series of breast and ovarian cancer cases and matched controls.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"CompositeMention\", \"entity\": \"breast and ovarian cancer\"}]"},{"user":"Due to strong linkage disequilibrium, these four sites generate only three haplotypes with a frequency > 1.3%.The most common haplotypes, defined by the alleles Gln356Pro871Glu1038Ser1613 and Gln356Leu871Gly1038Gly1613, have frequencies of 0.57 and 0.32 respectively, and these frequencies do not differ significantly between patient and control groups.Thus the most common polymorphisms of the BRCA1 gene do not make a significant contribution to breast or ovarian cancer risk.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"breast or ovarian cancer\"}]"},{"user":"However, our data suggest that the Arg356 allele may have a different genotype distribution in breast cancer patients from that in controls (Arg356 homozygotes are more frequent in the control groups, P = 0.01), indicating that it may be protective against breast cancer\nMutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"non-papillary renal cell carcinomas\"}]"},{"user":"To define the possible role of the VHL gene in the development of sporadic renal cell carcinomas, 91 different parenchymal tumours of the kidney have been investigated for mutation of the VHL gene by single strand conformation polymorphism (SSCP) and\/or heteroduplex (HD) techniques.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"SpecificDisease\", \"entity\": \"sporadic renal cell carcinomas\"}, {\"category\": \"DiseaseClass\", \"entity\": \"parenchymal tumours of the kidney\"}, {\"category\": \"Modifier\", \"entity\": \"VHL\"}]"},{"user":"Chromosome 3p deletion was detected in 98 per cent of non-papillary renal cell carcinomas and in 25 per cent of chromophobe renal cell carcinomas.In 22 of the 43 non-papillary renal cell carcinomas, abnormally migrating DNA bands were detected by SSCP and\/or HD analysis.No mobility shift was seen in any of the 23 chromophobe renal cell carcinomas.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"non-papillary renal cell carcinomas\"}, {\"category\": \"SpecificDisease\", \"entity\": \"renal cell carcinomas\"}, {\"category\": \"SpecificDisease\", \"entity\": \"non-papillary renal cell carcinomas\"}, {\"category\": \"SpecificDisease\", \"entity\": \"renal cell carcinomas\"}]"},{"user":"In addition, 15 papillary renal cell tumours and ten renal oncocytomas, which are characterized by genetic changes other than loss of chromosome 3p sequences, were analysed for mutation of the VHL gene.None of these tumours showed abnormal migration patterns.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"papillary renal cell tumours\"}, {\"category\": \"SpecificDisease\", \"entity\": \"renal oncocytomas\"}, {\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tumours\"}]"},{"user":"The results indicate that mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinoma\nComparative genome mapping of the ataxia-telangiectasia region in mouse, rat, and Syrian hamster.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"SpecificDisease\", \"entity\": \"non-papillary renal cell carcinoma\"}, {\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}]"},{"user":"Chromosomal locations of the Atm (ataxia-telangiectasia (AT) -mutated) and Acat1 (mitochondrial acetoacetyl-CoA thiolase) genes in mouse, rat, and Syrian hamster were determined by direct R-banding FISH.Both genes were colocalized to the C-D band of mouse chromosome 9, the proximal end of q24.1 of rat chromosome 8, and qa4-qa5 of Syrian hamster chromosome 12.The regions in the mouse and rat were homologous to human chromosome 11q.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"Modifier\", \"entity\": \"AT\"}]"},{"user":"Fine genetic linkage mapping of the mouse AT\nTumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus within human chromosome 10pter-q11.Prostate cancer is the second leading cause of male cancer deaths in the United States.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"AT\"}, {\"category\": \"Modifier\", \"entity\": \"Tumor\"}, {\"category\": \"SpecificDisease\", \"entity\": \"prostate carcinoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Prostate cancer\"}, {\"category\": \"Modifier\", \"entity\": \"cancer\"}]"},{"user":"Yet, despite a large international effort, little is known about the molecular mechanisms that underlie this devastating disease.Prostate secretory epithelial cells and androgen-dependent prostate carcinomas undergo apoptosis in response to androgen deprivation and, furthermore, most prostate carcinomas become androgen independent and refractory to further therapeutic manipulations during disease progression.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"prostate carcinomas\"}, {\"category\": \"SpecificDisease\", \"entity\": \"prostate carcinomas\"}]"},{"user":"Definition of the genetic events that trigger apoptosis in the prostate could provide important insights into critical pathways in normal development as well as elucidate the perturbations of those key pathways in neoplastic transformation.We report the functional definition of a novel genetic locus within human chromosome 10pter-q11 that mediates both in vivo tumor suppression and in vitro apoptosis of prostatic adenocarcinoma cells.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"prostatic adenocarcinoma\"}]"},{"user":"A defined fragment of human chromosome 10 was transferred via microcell fusion into a prostate adenocarcinoma cell line.Microcell hybrids containing only the region 10pter-q11 were suppressed for tumorigenicity following injection of microcell hybrids into nude mice.Furthermore, the complemented hybrids undergo programmed cell death in vitro via a mechanism that does not require nuclear localization of p53.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"prostate adenocarcinoma\"}]"},{"user":"These data functionally define a novel genetic locus, designated PAC1, for prostate adenocarcinoma 1, involved in tumor suppression of human prostate carcinoma and furthermore strongly suggest that the cell death pathway can be functionally restored in prostatic adenocarcinoma\nPhenotypic and genotypic overlap between atelosteogenesis type 2 and diastrophic dysplasia.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"prostate carcinoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"prostatic adenocarcinoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"atelosteogenesis type 2\"}, {\"category\": \"SpecificDisease\", \"entity\": \"diastrophic dysplasia\"}]"},{"user":"Mutations in the diastrophic dysplasia sulfate transporter gene DTDST have been associated with a family of chondrodysplasias that comprises, in order of increasing severity, diastrophic dysplasia (DTD), atelosteogenesis type 2 (AO2), and achondrogenesis type 1B (ACG1B).","assistant":"[{\"category\": \"Modifier\", \"entity\": \"diastrophic dysplasia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"chondrodysplasias\"}, {\"category\": \"SpecificDisease\", \"entity\": \"diastrophic dysplasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DTD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"atelosteogenesis type 2\"}, {\"category\": \"SpecificDisease\", \"entity\": \"AO2\"}, {\"category\": \"SpecificDisease\", \"entity\": \"achondrogenesis type 1B\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ACG1B\"}]"},{"user":"To learn more about the molecular basis of DTDST chondrodysplasias and about genotype-phenotype correlations, we studied fibroblast cultures of three new patients  one with AO-2, one with DTD, and one with an intermediate phenotype (AO2\/DTD).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"DTDST chondrodysplasias\"}, {\"category\": \"SpecificDisease\", \"entity\": \"AO-2\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DTD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"AO2\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DTD\"}]"},{"user":"Reduced incorporation of inorganic sulfate into macromolecules was found in all three.Each of the three patients was found to be heterozygous for a c862t transition predicting a R279W substitution in the third extracellular loop of DTDST.","assistant":"]"},{"user":"In two patients (DTD and AO2\/DTD), no other structural mutation was found, but polymerase chain reaction amplification and single-strand conformation polymorphism analysis of fibroblast cDNA showed reduced mRNA levels of the wild-type DTDST allele  these two patients may be compound heterozygotes for the \" Finnish \" mutation (as yet uncharacterized at the DNA level), which causes reduced expression of DTDST.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"DTD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"AO2\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DTD\"}]"},{"user":"The third patient (with AO2) had the R279W mutation compounded with a novel mutation, the deletion of cytosine 418 (delta c418), predicting a frameshift with premature termination.Also the delta c418 allele was underrepresented in the cDNA, in accordance with previous observations that premature stop codons reduce mRNA levels.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"AO2\"}]"},{"user":"The presence of the DTDST R279W mutation in a total of 11 patients with AO2 or DTD emphasizes the overlap between these conditions.This mutation has not been found so far in 8 analyzed ACG1B\nCloning of the homogentisate 1,2-dioxygenase gene, the key enzyme of alkaptonuria in mouse.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"AO2\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DTD\"}, {\"category\": \"Modifier\", \"entity\": \"ACG1B\"}, {\"category\": \"SpecificDisease\", \"entity\": \"alkaptonuria\"}]"},{"user":"We determined 48 amino acid residues from five peptides from the homogeneous monomer of homogentisate 1, 2-dioxygenase (HGO; E. C. 1.13.11.15) of mouse liver.After digestion with trypsin, peptides were separated by reversed phase chromatography and amino acid sequenced.The deduced codon sequence of three peptides was used to derive degenerated oligomeres.","assistant":"]"},{"user":"By combining these oligos, we were able to amplify fragments from 100 to 300 bases (b) from mouse liver cDNA by polymerase chain reaction after reverse transcription (RT-PCR).A fragment of 200 b was cloned and used as a probe to screen a mouse liver cDNA library.One clone from this library contained the complete cDNA-insert for HGO as determined by sequencing.The cDNA encodes for a protein of 50 kDa, as predicted.","assistant":"]"},{"user":"The cDNA of mouse HGO has an overall identity of 41% to the corresponding gene hmgA from Aspergillus.Sequence similarities to human expressed sequence tags (EST) clones ranged from 70% to 20%.The positions of 122 conserved amino acids could be determined by multiple sequence alignment.We identified one first intron of 928 b in the mouse gene.The gene for HGO seems to be expressed in various tissues, as shown by RT-PCR on different cDNAs.","assistant":"]"},{"user":"FISH experiments with the whole murine cDNA as probe clearly revealed signals at the human chromosomal band 3q13.3-q21.This corresponds well to the previous assignment of the locus for the human alkaptonuria gene (AKU) to the same chromosomal region by multipoint linkage analysis.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"alkaptonuria\"}]"},{"user":"We therefore conclude that the HGO cDNA encodes the gene responsible for alkaptonuria\nAbnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice.Myotonic dystrophy (DM) is commonly associated with CTG repeat expansions within the gene for DM-protein kinase (DMPK).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"alkaptonuria\"}, {\"category\": \"Modifier\", \"entity\": \"myotonic dystrophy\"}, {\"category\": \"DiseaseClass\", \"entity\": \"myopathy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Myotonic dystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DM\"}]"},{"user":"The effect of altered expression levels of DMPK, which is ubiquitously expressed in all muscle cell lineages during development, was examined by disrupting the endogenous Dmpk gene and overexpressing a normal human DMPK transgene in mice.Nullizygous (-\/-) mice showed only inconsistent and minor size changes in head and neck muscle fibres at older age, animals with the highest DMPK transgene expression showed hypertrophic cardiomyopathy and enhanced neonatal mortality.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"hypertrophic cardiomyopathy\"}]"},{"user":"However, both models lack other frequent DM symptoms including the fibre-type dependent atrophy, myotonia, cataract and male-infertility\nMolecular bases of combined subtotal deficiencies of C6 and C7: their effects in combination with other C6 and C7 deficiencies.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"DM\"}, {\"category\": \"SpecificDisease\", \"entity\": \"atrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"myotonia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"cataract\"}, {\"category\": \"SpecificDisease\", \"entity\": \"male-infertility\"}, {\"category\": \"SpecificDisease\", \"entity\": \"combined subtotal deficiencies of C6 and C7\"}, {\"category\": \"CompositeMention\", \"entity\": \"C6 and C7 deficiencies\"}]"},{"user":"Combined subtotal deficiency of C6 and C7, in which both proteins are expressed at very low levels, has been observed in homozygous form in two families.A defect at the 5 splice donor site of intron 15 of the C6 gene explains the low molecular weight of the C6 protein and is probably responsible for its low expressed concentration.The C7 defect is more enigmatic  the protein is of normal molecular weight, low circulating concentration, and altered isoelectric point.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Combined subtotal deficiency of C6 and C7\"}]"},{"user":"An Arg > Ser codon substitution in exon 11 is the only molecular alteration within the mature C7 protein.These defects are associated with a characteristic set of polymorphic DNA markers in the C6\/C7 region, forming a distinct haplotype.The haplotype has been found in combination with a number of other haplotypes containing defective genes that lead either to C6 or C7 deficiency, but with different consequences.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"C6 or C7 deficiency\"}]"},{"user":"Where it is combined with a C6-deficient\nConstitutively methylated CpG dinucleotides as mutation hot spots in the retinoblastoma gene (RB1).","assistant":"[{\"category\": \"Modifier\", \"entity\": \"C6-deficient\"}, {\"category\": \"Modifier\", \"entity\": \"retinoblastoma\"}]"},{"user":"A wide spectrum of mutations, ranging from point mutations to large deletions, have been described in the retinoblastoma\nThe TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"retinoblastoma\"}, {\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"Recent work has identified a mouse gene (tsg101) whose inactivation in fibroblasts results in cellular transformation and the ability to produce metastatic tumors in nude mice.Here, we report that the human homolog, TSG101, which we isolated and mapped to chromosome 11, bands 15.1-15 1-15.2, a region proposed to contain tumor suppressor gene (s), is mutated at high frequency in human breast cancer.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"metastatic tumors\"}, {\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"In 7 of 15 uncultured primary human breast carcinomas, intragenic deletions were shown in TSG101 genomic DNA and transcripts by gel and sequence analysis, and mutations affecting two TSG101 alleles were identified in four of these cancers.No TSG101 defects were found in matched normal breast tissue from the breast cancer patients.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast carcinomas\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancers\"}, {\"category\": \"Modifier\", \"entity\": \"breast cancer\"}]"},{"user":"These findings strongly implicate TSG101 mutations in human breast cancer\nThe Emery-Dreifuss muscular dystrophy protein, emerin, is a nuclear membrane protein.A large fragment of emerin cDNA was prepared by PCR and expressed as a recombinant protein in Escherichia coli.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"Modifier\", \"entity\": \"Emery-Dreifuss muscular dystrophy\"}]"},{"user":"Using this as immunogen, we prepared a panel of 12 monoclonal antibodies which recognise at least four different epitopes on emerin in order to ensure that emerin can be distinguished from non-specific cross-reacting proteins.All the mAbs recognised a 34 kDa protein in all tissues tested, though minor emerin-related bands were also detected in some tissues.Immunofluorescence microscopy showed that emerin is located at the nuclear rim in all tissues examined.","assistant":"]"},{"user":"A muscle biopsy from an Emery-Dreifuss muscular dystrophy (EMDM) patient showed complete absence of emerin by both Western blotting and immunohistochemistry, suggesting a simple diagnostic antibody test for EDMD\nInfluence of PAX6 gene dosage on development: overexpression causes severe eye abnormalities.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"Emery-Dreifuss muscular dystrophy\"}, {\"category\": \"Modifier\", \"entity\": \"EMDM\"}, {\"category\": \"Modifier\", \"entity\": \"EDMD\"}, {\"category\": \"DiseaseClass\", \"entity\": \"eye abnormalities\"}]"},{"user":"Aniridia in man and Small eye in mice are semidominant developmental disorders caused by mutations within the paired box gene PAX6.Whereas heterozygotes suffer from iris hypoplasia, homozygous mice lack eyes and nasal cavities and exhibit brain abnormalities.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Aniridia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"semidominant developmental disorders\"}, {\"category\": \"SpecificDisease\", \"entity\": \"iris hypoplasia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"brain abnormalities\"}]"},{"user":"To investigate the role of gene dosage in more detail, we have generated yeast artificial chromosome transgenic mice carrying the human PAX6 locus.When crossed onto the Small eye background, the transgene rescues the mutant phenotype.Strikingly, mice carrying multiple copies on a wild-type background show specific developmental abnormalities of the eye, but not of other tissues expressing the gene.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"developmental abnormalities of the eye\"}]"},{"user":"Thus, at least five different eye phenotypes are associated with changes in PAX6 expression.We provide evidence that not only reduced, but also increased levels of transcriptional regulators can cause developmental defects\nFounding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"developmental defects\"}, {\"category\": \"CompositeMention\", \"entity\": \"hereditary breast and ovarian cancer\"}]"},{"user":"Nine different germ-line mutations in the BRCA1 breast and ovarian cancer susceptibility gene were identified in 15 of 47 kindreds from southern Sweden, by use of SSCP and heteroduplex analysis of all exons and flanking intron region and by a protein-truncation test for exon 11, followed by direct sequencing.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"breast and ovarian cancer\"}]"},{"user":"All but one of the mutations are predicted to give rise to premature translation termination and include seven frameshift insertions or deletions, a nonsense mutation, and a splice acceptor site mutation.The remaining mutation is a missense mutation (Cys61Gly) in the zinc-binding motif.","assistant":"]"},{"user":"Four novel Swedish founding mutations were identified  the nucleotide 2595 deletion A was found in five families, the C 1806 T nonsense mutation in three families, the 3166 insertion TGAGA in three families, and the nucleotide 1201 deletion 11 in two families.Analysis of the intragenic polymorphism D17S855 supports common origins of the mutations.","assistant":"]"},{"user":"Eleven of the 15 kindreds manifesting BRCA1 mutations were breast-ovarian cancer families, several of them with a predominant ovarian cancer phenotype.The set of 32 families in which no BRCA1 alterations were detected included 1 breast-ovarian cancer kindred manifesting clear linkage to the BRCA1 region and loss of the wild-type chromosome in associated tumors.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"breast-ovarian cancer\"}, {\"category\": \"Modifier\", \"entity\": \"ovarian cancer\"}, {\"category\": \"Modifier\", \"entity\": \"breast-ovarian cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tumors\"}]"},{"user":"Other tumor types found in BRCA1 mutation\/haplotype carriers included prostatic, pancreas, skin, and lung cancer, a malignant melanoma, an oligodendroglioma, and a carcinosarcoma.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"CompositeMention\", \"entity\": \"prostatic, pancreas, skin, and lung cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"malignant melanoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"oligodendroglioma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"carcinosarcoma\"}]"},{"user":"In all, 12 of 16 kindreds manifesting BRCA1 mutation or linkage contained ovarian cancer, as compared with only 6 of the remaining 31 families (P <.001).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"ovarian cancer\"}]"},{"user":"The present study confirms the involvement of BRCA1 in disease predisposition for a subset of hereditary breast cancer families often characterized by ovarian cancers\nThe DCC protein and prognosis in colorectal cancer.BACKGROUND  Allelic loss of chromosome 18q predicts a poor outcome in patients with stage II colorectal cancer.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"hereditary breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ovarian cancers\"}, {\"category\": \"SpecificDisease\", \"entity\": \"colorectal cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"stage II colorectal cancer\"}]"},{"user":"Although the specific gene inactivated by this allelic loss has not been elucidated, the DCC (deleted in colorectal cancer) gene is a candidate.We investigated whether the expression of the DCC protein in tumor cells is a prognostic marker in colorectal carcinoma.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"colorectal cancer\"}, {\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"SpecificDisease\", \"entity\": \"colorectal carcinoma\"}]"},{"user":"METHODS  The expression of DCC was evaluated immunohistochemically in 132 paraffin-embedded samples from patients with curatively resected stage II and III colorectal carcinomas.The Cox proportional-hazards model was used to adjust for covariates including age, sex, tumor site, degree of tumor differentiation, and use of adjuvant therapy.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"stage II and III colorectal carcinomas\"}, {\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"Modifier\", \"entity\": \"tumor\"}]"},{"user":"RESULTS  The expression of DCC was a strong positive predictive factor for survival in both stage II and stage III colorectal carcinomas.In patients with stage II disease whose tumors expressed DCC, the five-year survival rate was 94.3 percent, whereas in patients with DCC-negative tumors, the survival rate was 61.6 percent (P < 0.001).","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"stage II and stage III colorectal carcinomas\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tumors\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DCC-negative tumors\"}]"},{"user":"In patients with stage III disease, the respective survival rates were 59.3 percent and 33.2 percent (P = 0.03).CONCLUSIONS  DCC is a prognostic marker in patients with stage II or stage III colorectal cancer.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"stage III disease\"}, {\"category\": \"CompositeMention\", \"entity\": \"stage II or stage III colorectal cancer\"}]"},{"user":"In stage II colorectal carcinomas, the absence of DCC identifies a subgroup of patients with lesions that behave like stage III cancers\nGene therapy for phenylketonuria.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"stage II colorectal carcinomas\"}, {\"category\": \"DiseaseClass\", \"entity\": \"stage III cancers\"}, {\"category\": \"SpecificDisease\", \"entity\": \"phenylketonuria\"}]"},{"user":"Classical phenylketonuria (PKU) is an autosomal recessive disorder caused by a deficiency of hepatic phenylalanine hydroxylase (PAH).Limitations of the current dietary treatment for PKU have led to the development of potential treatments based on somatic gene transfer.Three different vector systems have been examined.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"phenylketonuria\"}, {\"category\": \"SpecificDisease\", \"entity\": \"PKU\"}, {\"category\": \"DiseaseClass\", \"entity\": \"autosomal recessive disorder\"}, {\"category\": \"SpecificDisease\", \"entity\": \"deficiency of hepatic phenylalanine hydroxylase\"}, {\"category\": \"SpecificDisease\", \"entity\": \"PKU\"}]"},{"user":"Vectors derived from a recombinant retrovirus or a DNA\/protein complex can efficiently transduce the PAH cDNA into PAH-deficient hepatocytes in vitro, but the application of these vector systems is presently limited by their low transduction efficiency in vivo.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"PAH-deficient\"}]"},{"user":"In contrast, a vector derived from a recombinant adenovirus can restore 10% -80% of normal hepatic PAH activity into PAH-deficient mice, which completely normalizes serum phenylalanine levels.This treatment is transient and cannot be effectively re-administered due to the presence of neutralizing antibodies directed against the recombinant adenoviral vector.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"PAH-deficient\"}]"},{"user":"However, these findings suggest that PKU\nIdentification of a RING protein that can interact in vivo with the BRCA1 gene product.The hereditary breast and ovarian cancer gene, BRCA1, encodes a large polypeptide that contains the cysteine-rich RING motif, a zinc-binding domain found in a variety of regulatory proteins.Here we describe a novel protein that interacts in vivo with the N-terminal region of BRCA1.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"PKU\"}, {\"category\": \"Modifier\", \"entity\": \"hereditary breast and ovarian cancer\"}]"},{"user":"This BRCA1-associated RING domain (BARD1) protein contains an N-terminal RING motif, three tandem ankyrin repeats, and a C-terminal sequence with significant homology to the phylogenetically conserved BRCT domains that lie near the C terminus of BRCA1.","assistant":"]"},{"user":"The BARD1\/BRCA1 interaction is disrupted by BRCA1 missense mutations that segregate with breast cancer susceptibility, indicating that BARD1 may be involved in mediating tumour\nWiskott-Aldrich syndrome: no strict genotype-phenotype correlations but clustering of missense mutations in the amino-terminal part of the WASP gene product.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"breast cancer\"}, {\"category\": \"Modifier\", \"entity\": \"tumour\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Wiskott-Aldrich syndrome\"}]"},{"user":"The Wiskott-Aldrich syndrome protein (WASP) gene was found to be mutated in patients presenting with WAS and in patients showing X-linked thrombocytopenia.Mutation analysis in 19 families of German, Swiss and Turkish descent by single-strand conformation polymorphism and sequencing resulted in the detection of seven novel and 10 known mutations.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"Wiskott-Aldrich syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"WAS\"}, {\"category\": \"SpecificDisease\", \"entity\": \"X-linked thrombocytopenia\"}]"},{"user":"A striking clustering of missense mutations in the first four exons contrasted with a random distribution of nonsense mutations.More than 85% of all known missense mutations were localized in the amino-terminal stretch of the WASP gene product; this region contained a mutational hot spot at codon 86.","assistant":"]"},{"user":"No genotype-phenotype correlation emerged after a comparison of the identified mutations with the resulting clinical picture for a classical WAS\nAutosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"WAS\"}, {\"category\": \"SpecificDisease\", \"entity\": \"hyperparathyroidism and jaw tumor syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"renal hamartomas\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cystic kidney disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"renal hamartomas\"}]"},{"user":"Hereditary hyperparathyroidism-jaw tumor syndrome (HPT-JT) is an autosomal dominant disease (OMIM 145001) that has recently been mapped to chromosomal region 1q21-q32 (HRPT2).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Hereditary hyperparathyroidism-jaw tumor syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HPT-JT\"}, {\"category\": \"DiseaseClass\", \"entity\": \"autosomal dominant disease\"}]"},{"user":"Here we report two families with HPT-JT syndrome in which adult renal hamartomas or cystic kidney disease were prominent associated features, possibly representing a new phenotypic variant of the HPT-JT syndrome.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"HPT-JT syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"adult renal hamartomas\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cystic kidney disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HPT-JT syndrome\"}]"},{"user":"In the first family, renal lesions were present in five out of six affected individuals, whereas HPT and JT were seen in four and two cases, respectively.In the second family, JT was found in three of the five affected individuals and two affected members also exhibited polycystic kidney disease.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"renal lesions\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HPT\"}, {\"category\": \"SpecificDisease\", \"entity\": \"JT\"}, {\"category\": \"SpecificDisease\", \"entity\": \"JT\"}, {\"category\": \"SpecificDisease\", \"entity\": \"polycystic kidney disease\"}]"},{"user":"The possibility of the latter cosegregating as a separate autosomal dominant gene can not be ruled out.A sex-dependent penetrance of primary HPT, resulting in predominantly male-affected cases was evident in the two families.Twenty microsatellite markers in the HRPT2 region were typed, in addition to markers in the multiple endocrine neoplasia (MEN) types 1 and 2 regions at 11q13 and 10q11.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"primary HPT\"}, {\"category\": \"Modifier\", \"entity\": \"multiple endocrine neoplasia (MEN) types 1 and 2\"}]"},{"user":"The disease in these two kindreds was linked to five markers in the 1q21-q32 region (logarithm-of-odds scores  3.2-4 2-4.2), whereas linkage to the MEN1 and MEN2 regions was excluded.Meiotic recombinations detected in affected individuals placed the locus telomeric of D1S215, thus narrowing the HRPT2 region from > 60 to approximately 34 centimorgans.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"MEN1\"}, {\"category\": \"Modifier\", \"entity\": \"MEN2\"}]"},{"user":"Loss of heterozygosity was studied in seven renal hamartomas from two affected individuals in the first family, as well as in a jaw tumor and a parathyroid tumor from the second family.All renal hamartomas showed loss of heterozygosity at the 1q21-q32 region.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"renal hamartomas\"}, {\"category\": \"SpecificDisease\", \"entity\": \"jaw tumor\"}, {\"category\": \"SpecificDisease\", \"entity\": \"parathyroid tumor\"}, {\"category\": \"SpecificDisease\", \"entity\": \"renal hamartomas\"}]"},{"user":"The losses invariably involved the wild type allele derived from the unaffected parent, suggesting the inactivation of a tumor\nHeterodimer formation and activity in the human enzyme galactose-1-phosphate uridylyltransferase.One of the fundamental questions concerning expression and function of dimeric enzymes involves the impact of naturally occurring mutations on subunit assembly and heterodimer activity.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"tumor\"}]"},{"user":"This question is of particular interest for the human enzyme galactose-l-phosphate uridylyl-transferase (GALT), impairment of which results in the inherited metabolic disorder galactosemia, because many if not most patients studied to date are compound heterozygotes rather than true molecular homozygotes.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"inherited metabolic disorder\"}, {\"category\": \"SpecificDisease\", \"entity\": \"galactosemia\"}]"},{"user":"Furthermore, the broad range of phenotypic severity observed in these patients raises the possibility that allelic combination, not just allelic constitution, may play some role in determining outcome.In the work described herein, we have selected two distinct naturally occurring null mutations of GALT, Q188R and R333W, and asked the questions (i) what are the impacts of these mutations on subunit assembly, and (ii) if heterodimers do form, are they active ?","assistant":"]"},{"user":"To answer these questions, we have established a yeast system for the coexpression of epitope-tagged alleles of human GALT and investigated both the extent of specific GALT subunit interactions and the activity of defined heterodimer pools.We have found that both homodimers and heterodimers do form involving each of the mutant subunits tested and that both heterodimer pools retain substantial enzymatic activity.","assistant":"]"},{"user":"These results are significant not only in terms of their implications for furthering our understanding of galactosemia\nBRCA1 R841W: a strong candidate for a common mutation with moderate phenotype.BRCA1 mutations cause increased risk for breast and ovarian cancer, frequently of early onset.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"galactosemia\"}, {\"category\": \"CompositeMention\", \"entity\": \"breast and ovarian cancer\"}]"},{"user":"Many different mutations occur in BRCA1, including several examples of recurrent mutations, each of which accounts for a significant number of families with heritable cancer predisposition.These common mutations have an etiological role in many breast and ovarian cancer cases and provide the opportunity to examine genotype-phenotype correlations and genotype-environment interactions in individuals with the identical BRCA1 lesion.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"cancer\"}, {\"category\": \"Modifier\", \"entity\": \"breast and ovarian cancer\"}]"},{"user":"We report a novel missense change in BRCA1, 2640 C-- > T (R841W), found in 3 cases from a subject group of 305 breast and 79 ovarian cancer cases from Orange County, CA.These are consecutive, population-based cases not selected for age or family history.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"breast and 79 ovarian cancer\"}]"},{"user":"In all three cases, there is a strong family history of breast, ovarian, or other cancers possibly related to a BRCA1 defect and family members showed a high concordance of cancer incidence with the presence of R841W.The age of cancer onset was not always distinct from typical sporadic cases.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"breast, ovarian, or other cancers\"}, {\"category\": \"Modifier\", \"entity\": \"cancer\"}, {\"category\": \"Modifier\", \"entity\": \"cancer\"}]"},{"user":"Testing of a sample of 413 unrelated individuals to examine the hypothesis that R841W might be a rare polymorphism detected one additional instance in a woman with breast cancer diagnosed at age 77 years, and cancer in one parent.R841W is likely to be an etiologically significant lesion with involvement in close to 1% (95% confidence interval of 0-1.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancer\"}]"},{"user":"7%) of all breast and ovarian cancers\nIndependent origin of single and double mutations in the human glucose 6-phosphate dehydrogenase gene.The vast majority of both polymorphic and sporadic G6PD variants are due to single missense mutations.In the four polymorphic variants that have two point mutations, one of the mutations is always 376 A-- > G (126 Asn-- > Asp), which on its own gives rise to the nondeficient polymorphic variant, G6PD A.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"breast and ovarian cancers\"}]"},{"user":"In a study of G6PD deficient patients who presented with clinical favism in Spain, we have found a new polymorphic variant that we have called G6PD Malaga, whose only abnormality is a 542 A-- > T (181 Asp-- > Val) mutation.This is the same mutation as previously found in association with the mutation of G6PD A in the double mutant, G6PD Santamaria.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"G6PD deficient\"}, {\"category\": \"SpecificDisease\", \"entity\": \"favism\"}]"},{"user":"G6PD Malaga is associated with enzyme deficiency\nFISH studies in a patient with sporadic aniridia and t(7;11) (q31.2;p13).A 2 year old female presenting with bilateral sporadic aniridia was found to have an apparently balanced reciprocal translocation with a chromosome 11 breakpoint within band p13.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"enzyme deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"sporadic aniridia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"bilateral sporadic aniridia\"}]"},{"user":"Fluorescence in situ hybridisation (FISH) studies with distal 11p13 specific cosmids showed that the chromosome 11 breakpoint lay between the aniridia (PAX6) locus and a region approximately 100 kb distal to PAX6 defined by the cosmid FO2121.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"aniridia\"}]"},{"user":"Although this patient did not have a detectable deletion within PAX6, her aniridia may have resulted from a disruption of the distal chromatin domain containing either enhancers or regulators for PAX6.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"aniridia\"}]"},{"user":"This case may therefore be another example of aniridia caused by a position effect as recently described in two familial aniridia patients in which the phenotype cosegregated with chromosome abnormalities\nOvarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"aniridia\"}, {\"category\": \"Modifier\", \"entity\": \"familial aniridia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"chromosome abnormalities\"}, {\"category\": \"Modifier\", \"entity\": \"Ovarian cancer\"}]"},{"user":"Women who carry a mutation in the BRCA1 gene (on chromosome 17q21), have an 80% risk of breast cancer and a 40% risk of ovarian cancer by the age of 70 (ref.1).The variable penetrance of BRCA1 suggests that other genetic and non-genetic factors play a role in tumourigenesis in these individuals.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ovarian cancer\"}]"},{"user":"The HRAS1 variable number of tandem repeats (VNTR) polymorphism, located 1 kilobase (kb) downstream of the HRAS1 proto-oncogene (chromosome 11p15.5) is one possible genetic modifier of cancer penetrance.Individuals who have rare alleles of the VNTR have an increased risk of certain types of cancers, including breast cancer (2-4).","assistant":"[{\"category\": \"Modifier\", \"entity\": \"cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancers\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"To investigate whether the presence of rare HRAS1 alleles increases susceptibility to hereditary breast and ovarian cancer, we have typed a panel of 307 female BRCA1 carriers at this locus using a PCR-based technique.The risk for ovarian cancer was 2.11 times greater for BRCA1 carriers harbouring one or two rare HRAS1 alleles, compared to carriers with only common alleles (P = 0.015).","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"hereditary breast and ovarian cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ovarian cancer\"}]"},{"user":"The magnitude of the relative risk associated with a rare HRAS1 allele was not altered by adjusting for the other known risk factors for hereditary ovarian cancer (5).Susceptibility to breast cancer did not appear to be affected by the presence of rare HRAS1 alleles.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"hereditary ovarian cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"This study is the first to show the effect of a modifying gene on the penetrance of an inherited cancer syndrome\nA previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"inherited cancer syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Li-Fraumeni syndrome\"}]"},{"user":"We report details of a family with classic Li-Fraumeni syndrome in which there is a mutation in codon 344 of the tumour suppressor gene TP53.Codon 344 is a key residue within the tetramerisation domain, and the amino acid substitution of a proline for a leucine is predicted to have profound implications for tetramerisation and potentially DNA binding.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Li-Fraumeni syndrome\"}, {\"category\": \"Modifier\", \"entity\": \"tumour\"}]"},{"user":"This is the first report of a mutation at this residue in either sporadic tumours or in the germline and the first report of a germline mutation within the tetramerisation domain.The family does not appear to be remarkable in the spectrum of tumours, and there is loss of the wild-type allele in a leiomyosarcoma from the proband.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"sporadic tumours\"}, {\"category\": \"DiseaseClass\", \"entity\": \"tumours\"}, {\"category\": \"SpecificDisease\", \"entity\": \"leiomyosarcoma\"}]"},{"user":"A cell line has been established from the tumour\nTrinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"tumour\"}, {\"category\": \"Modifier\", \"entity\": \"myotonic dystrophy\"}]"},{"user":"Myotonic dystrophy, or dystrophia myotonica (DM), is an autosomal dominant multisystem disorder caused by the expansion of a CTG trinucleotide repeat in the 3 untranslated region of the DMPK protein kinase gene on chromosome 19q13.3 (refs 1-3).","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Myotonic dystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"dystrophia myotonica\"}, {\"category\": \"SpecificDisease\", \"entity\": \"DM\"}, {\"category\": \"DiseaseClass\", \"entity\": \"autosomal dominant multisystem disorder\"}]"},{"user":"Although the DM mutation was identified more than five years ago, the pathogenic mechanisms underlying this most prevalent form of hereditary adult neuromuscular disease remain elusive.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"DM\"}, {\"category\": \"DiseaseClass\", \"entity\": \"neuromuscular disease\"}]"},{"user":"Previous work from our laboratory demonstrated that a DNase l-hypersensitive site located adjacent to the repeats on the wild-type allele is eliminated by repeat expansion, indicating that large CTG-repeat arrays may be associated with a local chromatin environment that represses gene expression.Here we report that the hypersensitive site contains an enhancer element that regulates transcription of the adjacent DMAHP homeobox gene.","assistant":"]"},{"user":"Analysis of DMAHP expression in the cells of DM patients with loss of the hypersensitive site revealed a two- to fourfold reduction in steady-state DMAHP transcript levels relative to wild-type controls.Allele-specific analysis of DMAHP expression showed that steady-state transcript levels from the expanded allele were greatly reduced in comparison to those from the wild-type allele.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"DM\"}]"},{"user":"Together, these results demonstrate that CTG-repeat expansions can suppress local gene expression and implicate DMAHP in DM\nA mutation in autosomal dominant myotonia congenita affects pore properties of the muscle chloride channel.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"DM\"}, {\"category\": \"SpecificDisease\", \"entity\": \"autosomal dominant myotonia congenita\"}]"},{"user":"Autosomal dominant myotonia congenita is an inherited disorder of skeletal muscle\nMutation analysis of BRCA1 and BRCA2 in a male breast cancer population.A population-based series of 54 male breast cancer cases from Southern California were analyzed for germ-line mutations in the inherited breast\/ovarian cancer genes, BRCA1 and BRCA2.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Autosomal dominant myotonia congenita\"}, {\"category\": \"DiseaseClass\", \"entity\": \"inherited disorder of skeletal muscle\"}, {\"category\": \"Modifier\", \"entity\": \"male breast cancer\"}, {\"category\": \"Modifier\", \"entity\": \"male breast cancer\"}, {\"category\": \"Modifier\", \"entity\": \"inherited breast\/ovarian cancer\"}]"},{"user":"Nine (17%) of the patients had a family history of breast and\/or ovarian cancer in at least one first-degree relative.A further seven (13%) of the patients reported breast\/ovarian cancer in at least one second-degree relative and in no first-degree relatives.No germ-line BRCA1 mutations were found.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"breast and\/or ovarian cancer\"}, {\"category\": \"CompositeMention\", \"entity\": \"breast\/ovarian cancer\"}]"},{"user":"Two male breast cancer patients (4% of the total) were found to carry novel truncating mutations in the BRCA2 gene.Only one of the two male breast cancer patients carrying a BRCA2 mutation had a family history of cancer, with one case of ovarian cancer in a first-degree relative.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"male breast cancer\"}, {\"category\": \"Modifier\", \"entity\": \"male breast cancer\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ovarian cancer\"}]"},{"user":"The remaining eight cases (89%) of male breast cancer with a family history of breast\/ovarian cancer\nExpression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.The von Hippel-Lindau (VHL) disease product is thought to down-regulate transcription by antagonizing elongin-enhanced transcriptional elongation.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"male breast cancer\"}, {\"category\": \"CompositeMention\", \"entity\": \"breast\/ovarian cancer\"}, {\"category\": \"Modifier\", \"entity\": \"von Hippel-Lindau disease tumour\"}, {\"category\": \"Modifier\", \"entity\": \"von Hippel-Lindau (VHL) disease\"}]"},{"user":"Germline VHL gene mutations predispose to the development of retinal, cerebellar and spinal haemangioblastomas, renal cell carcinoma and phaeochromocytoma.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"CompositeMention\", \"entity\": \"retinal, cerebellar and spinal haemangioblastomas\"}, {\"category\": \"SpecificDisease\", \"entity\": \"renal cell carcinoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"phaeochromocytoma\"}]"},{"user":"In addition, somatic Inactivation of the VHL gene is frequent in sporadic renal cell carcinoma and haemangioblastoma.Regulation of transcript elongation is an important control mechanism for gene expression and the VHL gene might modify the expression of proto-oncogenes and growth suppressor genes during embryogenesis.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"SpecificDisease\", \"entity\": \"sporadic renal cell carcinoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"haemangioblastoma\"}, {\"category\": \"Modifier\", \"entity\": \"VHL\"}]"},{"user":"We therefore investigated the expression of VHL mRNA during human embryogenesis by in situ hybridization studies at 4, 6 and 10 weeks post conception.Although VHL mRNA was expressed in all three germ layers, strong expression was noted in the central nervous system, kidneys, testis and lung.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"Modifier\", \"entity\": \"VHL\"}]"},{"user":"Within the kidney, VHL mRNA was differentially expressed within renal tubules suggesting that the VHL gene product may have a specific role in kidney development.Two alternatively spliced VHL mRNAs characterized by inclusion (isoform I) or exclusion (isoform II) of exon 2 are transcribed in adult tissues.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"Modifier\", \"entity\": \"VHL\"}]"},{"user":"To investigate if the two isoforms are differentially expressed during embryogenesis, VHL mRNA was reverse transcribed from 13 fetal tissues (8-10 weeks gestation).The quantitative distribution of VHL mRNA within fetal tissues reflected that seen by in situ hybridization and the ratio of the two VHL isoforms was similar between tissues.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"Modifier\", \"entity\": \"VHL\"}]"},{"user":"Although the genes regulated by the VHL gene product have not yet been identified, our findings are compatible with the hypothesis that VHL\nScreening for ESR mutations in breast and ovarian cancer patients.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"Modifier\", \"entity\": \"VHL\"}, {\"category\": \"Modifier\", \"entity\": \"breast and ovarian cancer\"}]"},{"user":"In the present study, leukocyte DNA from 143 patients with familial clustering of breast and\/or ovarian cancer and tumour DNA from 96 breast carcinomas were screened for base mutations in the estrogen receptor gene (ESR).Three patients with a family history of cancer were carrying a Gly160Cys germline substitution.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"breast and\/or ovarian cancer\"}, {\"category\": \"Modifier\", \"entity\": \"tumour\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast carcinomas\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancer\"}]"},{"user":"This alteration was also detected in eight (four females and four males) of 729 controls (366 female, 363 males), indicating that the substitution probably represents a polymorphism.However, in the 229 female controls in whom family history of cancer was known, one of two who had a sister with breast cancer was carrying the variant allele.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"cancer\"}, {\"category\": \"SpecificDisease\", \"entity\": \"breast cancer\"}]"},{"user":"Hence, a possible clinical significance of the glycine into cysteine cannot be completely ruled out and should be further investigated.","assistant":"]"},{"user":"Somatic mutations were not detected in any of the tumours studied, and the present data do not provide support for somatic ESR base mutations as an important mechanism for hormonal therapy resistance in estrogen receptor-positive breast carcinomas\nIncreased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"tumours\"}, {\"category\": \"SpecificDisease\", \"entity\": \"estrogen receptor-positive breast carcinomas\"}, {\"category\": \"SpecificDisease\", \"entity\": \"coronary heart disease\"}]"},{"user":"Plasma high density lipoprotein (HDL) levels are strongly genetically determined and show a general inverse relationship with coronary heart disease (CHD).The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"coronary heart disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"CHD\"}]"},{"user":"A high prevalence of two different CETP gene mutations (D442G, 5.1%; intron 14G  A, 0.5%), was found in 3, 469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP (-35%) and increased HDL chol levels (+ 10% for D442G).However, the overall prevalence of definite CHD was 21% in men with mutations and 16% in men without mutations.The relative risk (RR) of CHD was 1.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"CHD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"CHD\"}]"},{"user":"43 in men with mutations (P <.05); after adjustment for CHD risk factors, the RR was 1.55 (P =.02); after additional adjustment for HDL levels, the RR was 1.68 (P =.008).Similar RR values were obtained for the D442G mutation alone.Increased CHD in men with mutations was primarily observed for HDL chol 41-60 mg\/dl; for HDL chol > 60 mg\/dl men with and without mutations had low CHD prevalence.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"CHD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"CHD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"CHD\"}]"},{"user":"Thus, genetic CETP deficiency appears to be an independent risk factor for CHD, primarily due to increased CHD\nAnalysis of meiotic segregation, using single-sperm typing: meiotic drive at the myotonic dystrophy locus.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"CETP deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"CHD\"}, {\"category\": \"Modifier\", \"entity\": \"CHD\"}, {\"category\": \"Modifier\", \"entity\": \"myotonic dystrophy\"}]"},{"user":"Meiotic drive at the myotonic dystrophy (DM) locus has recently been suggested as being responsible for maintaining the frequency, in the human population, of DM chromosomes capable of expansion to the disease state.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"myotonic dystrophy\"}, {\"category\": \"Modifier\", \"entity\": \"DM\"}, {\"category\": \"Modifier\", \"entity\": \"DM\"}]"},{"user":"In order to test this hypothesis, we have studied samples of single sperm from three individuals heterozygous at the DM locus, each with one allele larger and one allele smaller than 19 CTG repeats.To guard against the possible problem of differential PCR amplification rates based on the lengths of the alleles, the sperm were also typed at another closely linked marker whose allele size was unrelated to the allele size at the DM locus.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"DM\"}, {\"category\": \"Modifier\", \"entity\": \"DM\"}]"},{"user":"Using statistical models specifically designed to study single-sperm segregation data, we find no evidence of meiotic segregation distortion.The upper limit of the two-sided 95% confidence interval for the estimate of the common segregation probability for the three donors is at or below.515 for all models considered, and no statistically significant difference from.5 is detected in any of the models.","assistant":"]"},{"user":"This suggests that any greater amount of segregation distortion at the myotonic dystrophy\nIsolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype.A gene mutated in the human genetic disorder ataxia-telangiectasia (A-T), ATM, was recently identified by positional cloning.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"myotonic dystrophy\"}, {\"category\": \"Modifier\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"genetic disorder\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"A-T\"}]"},{"user":"ATM is a member of the phosphatidylinositol-3-kinase superfamily, some of which are protein kinases and appear to have important roles in cell cycle control and radiation signal transduction.We describe herein, to our knowledge, for the first time, the cloning of a full-length cDNA for ATM and correction of multiple aspects of the radio-sensitive phenotype of A-T cells by transfection with this cDNA.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"A-T\"}]"},{"user":"Overexpression of ATM cDNA in A-T cells enhanced the survival of these cells in response to radiation exposure, decreased radiation-induced chromosome aberrations, reduced radio-resistant DNA synthesis, and partially corrected defective cell cycle checkpoints and induction of stress-activated protein kinase.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"A-T\"}]"},{"user":"This correction of the defects in A-T\nThe spectrum of RB1 germ-line mutations in hereditary retinoblastoma.We have searched for germ-line RB1 mutations in 119 patients with hereditary retinoblastoma.Previous investigations by Southern blot hybridization and PCR fragment-length analysis had revealed mutations in 48 patients.Here we report on the analysis of the remaining 71 patients.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"A-T\"}, {\"category\": \"SpecificDisease\", \"entity\": \"hereditary retinoblastoma\"}, {\"category\": \"SpecificDisease\", \"entity\": \"hereditary retinoblastoma\"}]"},{"user":"By applying heteroduplex analysis, nonisotopic SSCP, and direct sequencing, we detected germ-line mutations resulting in premature termination codons or disruption of splice signals in 51 (72%) of the 71 patients.Four patients also showed rare sequence variants.No region of the RB1 gene was preferentially involved in single base substitutions.Recurrent transitions were observed at most of the 14 codons within the RB1.No mutation was observed in exons 25-27, although this region contains two CGA codons.","assistant":"]"},{"user":"This suggests that mutations within the 3-terminal region of the RB1 gene may not be oncogenic.When these data were combined with the results of our previous investigations, mutations were identified in a total of 99 (83%) of 119 patients.The spectrum comprises 15% large deletions, 26% small length alterations, and 42% base substitutions.","assistant":"]"},{"user":"No correlation between the location of frameshift or nonsense mutations and phenotypic features, including age at diagnosis, the number of tumor foci, and manifestation of nonocular tumors\nWiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization.The Rho family of GTPases control diverse biological processes, including cell morphology and mitogenesis.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"tumor\"}, {\"category\": \"DiseaseClass\", \"entity\": \"nonocular tumors\"}, {\"category\": \"Modifier\", \"entity\": \"Wiskott-Aldrich syndrome\"}]"},{"user":"We have identified WASP, the protein that is defective in Wiskott-Aldrich syndrome (WAS), as a novel effector for CDC42Hs, but not for the other Rho family members, Rac and Rho.This interaction is dependent on the presence of the G protein-binding domain.Cellular expression of epitope-tagged WASP produces clusters of WASP that are highly enriched in polymerized actin.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Wiskott-Aldrich syndrome\"}, {\"category\": \"SpecificDisease\", \"entity\": \"WAS\"}]"},{"user":"This clustering is not observed with a C-terminally deleted WASP and is inhibited by coexpression with dominant negative CDC42Hs-N17, but not with dominant negative forms of Rac or Rho.","assistant":"]"},{"user":"Thus, WASP provides a novel link between CDC42Hs and the actin cytoskeleton, which suggests a molecular mechanism for many of the cellular abnormalities in WAS\nAdult onset globoid cell leukodystrophy (Krabbe disease): analysis of galactosylceramidase cDNA from four Japanese patients.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"WAS\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Adult onset globoid cell leukodystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Krabbe disease\"}]"},{"user":"We examined galactosylceramidase (GALC) cDNA in four Japanese patients with adult onset globoid cell leukodystrophy (Krabbe disease; AO-GLD) by polymerase chain reaction\/single-strand conformation polymorphism (PCR-SSCP) analysis, subsequent sequence determination, and restriction enzyme digestion of PCR products, initial symptoms were the onset of slowly progressive spastic paraplegia from the middle of the second decade, and all patients had diminished GALC activity in their leukocytes.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"adult onset globoid cell leukodystrophy\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Krabbe disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"AO-GLD\"}, {\"category\": \"DiseaseClass\", \"entity\": \"spastic paraplegia\"}, {\"category\": \"DiseaseClass\", \"entity\": \"diminished GALC activity\"}]"},{"user":"We identified three missense mutations (I66M, G270D, L618S) and one exon-6 skipping (535-573del).Two of the patients had only the I66M mutant mRNA, and one only the G27OD mutant mRNA.The fourth patient carried a compound heterozygous mutation of 535-573del and L618S.To determine the enzymatic activities produced by these mutations, we constructed mutated GALC cDNAs and expressed them in COS-1 cells.","assistant":"]"},{"user":"Three mutations, viz., G270D, L618S, and exon-6 skipping (535-573del), produced diminished GALC activity as expected.The I66M mutation in the wild-type GALC cDNA (I289) had normal activity, but when this mutation and the V289 polymorphism were introduced into the same allele, it had decreased activity.Thus, the combination of a unique mutation and polymorphism causes conformational change in the GALC enzyme, resulting in low enzymatic activity.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"diminished GALC activity\"}]"},{"user":"AO-GLD mutations, including those found here, are located in the N-terminus (I66M, G270D, 535-573del) or C-terminus (L618S) of the GALC enzyme, whereas the reported mutations in the infantile form (IF-GLD) are in the central domain.This difference in mutation sites may affect the clinical features of GLD\nBRCA1 is secreted and exhibits properties of a granin.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"AO-GLD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"IF-GLD\"}, {\"category\": \"SpecificDisease\", \"entity\": \"GLD\"}]"},{"user":"Germline mutations in BRCA1 are responsible for most cases of inherited breast and ovarian cancer .However, the function of the BRCA1 protein has remained elusive.We now show that BRCA1 encodes a 190-kD protein with sequence homology and biochemical analogy to the granin protein family.Interestingly, BRCA2 also includes a motif similar to the granin consensus at the C terminus of the protein.","assistant":"[{\"category\": \"CompositeMention\", \"entity\": \"inherited breast and ovarian cancer\"}]"},{"user":"Both BRCA1 and the granins localize to secretory vesicles, are secreted by a regulated pathway, are post-translationally glycosylated and are responsive to hormones.As a regulated secretory protein, BRCA1 appears to function by a mechanism not previously described for tumour\nInsulin gene region contributes to genetic susceptibility to, but may not to low incidence of, insulin-dependent diabetes mellitus in Japanese.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"tumour\"}, {\"category\": \"SpecificDisease\", \"entity\": \"insulin-dependent diabetes mellitus\"}]"},{"user":"In the Caucasian population, it has been demonstrated that the insulin gene (INS) region contains the insulin-dependent diabetes mellitus locus (IDDM2).In the Japanese population, however, there has been no report demonstrating the contribution of IDDM2 to the pathogenesis of IDDM.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"insulin-dependent diabetes mellitus\"}, {\"category\": \"SpecificDisease\", \"entity\": \"IDDM\"}]"},{"user":"We conducted an association study of IDDM in a large number of Japanese subjects with multiple polymorphisms in INS region.We found a significant association of the INS region with IDDM.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"IDDM\"}, {\"category\": \"SpecificDisease\", \"entity\": \"IDDM\"}]"},{"user":"Alleles positively associated with IDDM in INS region were the same as those positively-associated with IDDM in Caucasian population, although positively-associated alleles are very common (allele frequencies > 0.9) in the Japanese general population.These data suggest that IDDM2 is involved in the genetic susceptibility to IDDM in Japanese.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"IDDM\"}, {\"category\": \"SpecificDisease\", \"entity\": \"IDDM\"}, {\"category\": \"SpecificDisease\", \"entity\": \"IDDM\"}]"},{"user":"The high frequencies of disease-associated alleles in the general population suggest that IDDM2 locus is not responsible for the low incidence of IDDM\nAssociation of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"IDDM\"}, {\"category\": \"DiseaseClass\", \"entity\": \"anxiety-related traits\"}]"},{"user":"Transporter-facilitated uptake of serotonin (5-hydroxytryptamine or 5-HT) has been implicated in anxiety in humans and animal models and is the site of action of widely used uptake-inhibiting antidepressant and antianxiety drugs.Human 5-HT transporter (5-HTT) gene transcription is modulated by a common polymorphism in its upstream regulatory region.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"anxiety\"}]"},{"user":"The short variant of the polymorphism reduces the transcriptional efficiency of the 5-HTT gene promoter, resulting in decreased 5-HTT expression and 5-HT uptake in lymphoblasts.","assistant":"]"},{"user":"Association studies in two independent samples totaling 505 individuals revealed that the 5-HTT polymorphism accounts for 3 to 4 percent of total variation and 7 to 9 percent of inherited variance in anxiety-related personality traits\nCloning and characterization of human very-long-chain acyl-CoA dehydrogenase cDNA, chromosomal assignment of the gene and identification in four patients of nine different mutations within the VLCAD gene.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"anxiety-related personality traits\"}]"},{"user":"Very-long-chain acyl-CoA dehydrogenase (VLCAD) is one of four straight-chain acyl-CoA dehydrogenase (ACD) enzymes, which are all nuclear encoded mitochondrial flavoproteins catalyzing the initial step in fatty acid beta-oxidation.We have used the very fast, Rapid Amplification of cDNA Ends (RACE) based strategy to obtain the sequence of cDNAs encoding human VLCAD from placenta and fibroblasts.","assistant":"]"},{"user":"Alignment of the predicted amino acid sequence of human VLCAD with those of the other human ACD enzymes revealed extensive sequence homology.Moreover, human VLCAD and human acyl-CoA oxidase showed extensive sequence homology corroborating the notion that these genes are evolutionarily related.Southern blot analysis of genomic DNA from hybrid cell lines was used to localize the VLCAD gene to human chromosome 17p11.2-p11.13105.","assistant":"]"},{"user":"Using Northern and Western blot analysis to investigate the tissue specific distribution of VLCAD mRNA and protein in several human tissues we showed that VLCAD is most abundant in heart and skeletal muscle.This agrees well with the fact that cardiac and muscle symptoms are characteristic for patients with VLCAD deficiency.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"VLCAD deficiency\"}]"},{"user":"Northern blot analysis and sequencing of cloned PCR amplified VLCAD cDNA from four unrelated patients with VLCAD deficiency\nGenetic bases of human complement C7 deficiency.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"VLCAD deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"complement C7 deficiency\"}]"},{"user":"Complement C7 deficiency (C7D) is associated frequently with recurrent bacterial infections, especially meningitis caused by Neisseria meningitidis.We report in this work the molecular bases of C7D in two unrelated Japanese males.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Complement C7 deficiency\"}, {\"category\": \"SpecificDisease\", \"entity\": \"C7D\"}, {\"category\": \"DiseaseClass\", \"entity\": \"bacterial infections\"}, {\"category\": \"DiseaseClass\", \"entity\": \"meningitis\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Neisseria meningitidis\"}, {\"category\": \"SpecificDisease\", \"entity\": \"C7D\"}]"},{"user":"We used exon-specific PCR\/single-strand conformation polymorphism analysis as a screening step for mutations.Subsequent direct sequencing of the target exons identified homozygous mutations in exon 16 of case 1 and in exon 15 of case 2.The mutation of case 1 was a homozygous T to A transversion at nucleotide 2250, the third nucleotide of the codon TGT for Cys728, leading to a stop codon TGA (C728X).","assistant":"]"},{"user":"In case 2, a homozygous 2-bp deletion (2137delTG\/2138delGT\/2139delTG) caused a frameshift, generating a premature termination codon 4 to 6 nucleotides downstream.Family study in case 1 confirmed the genetic nature of the defect.Moreover, we detected a novel polymorphism in intron 11 that presumably is linked to the mutation responsible for C7D in case 1.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"C7D\"}]"},{"user":"Our results indicate that the pathogenesis of C7D is heterogeneous like most of the other deficiencies of complement components\nDefective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"C7D\"}, {\"category\": \"DiseaseClass\", \"entity\": \"deficiencies of complement components\"}, {\"category\": \"Modifier\", \"entity\": \"von Willebrand\"}, {\"category\": \"SpecificDisease\", \"entity\": \"type IID von Willebrand disease\"}]"},{"user":"The same heterozygous T - > C transition at nt 8567 of the von Willebrand factor (vWF) transcript was found in two unrelated patients with type IID von Willebrand disease, with no other apparent abnormality.In one family, both alleles were normal in the parents and one sister; thus, the mutation originated de novo in the proposita.The second patient also had asymptomatic parents who, however, were not available for study.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"von Willebrand\"}, {\"category\": \"SpecificDisease\", \"entity\": \"type IID von Willebrand disease\"}]"},{"user":"The structural consequences of the identified mutation, resulting in the CyS2010 - > Arg substitution, were evaluated by expression of the vWF carboxyl-terminal domain containing residues 1366-2050.Insect cells infected with recombinant baculovirus expressing normal vWF sequence secreted a disulfide linked dimeric molecule with an apparent molecular mass of 150 kDa before reduction, yielding a single band of 80 kDa after disulfide bond reduction.","assistant":"]"},{"user":"In contrast, cells expressing the mutant fragment secreted a monomeric molecule of apparent molecular mass of 80 kDa, which remained unchanged after reduction.","assistant":"]"},{"user":"We conclude that CyS2010 is essential for normal dimerization of vWF subunits through disulfide bonding of carboxyl-terminal domains and that a heterozygous mutation in the corresponding codon is responsible for defective multimer formation in type IID von Willebrand disease\nAtaxia-telangiectasia: founder effect among north African Jews.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"type IID von Willebrand disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"Ataxia-telangiectasia\"}]"},{"user":"The ATM gene is responsible for the autosomal recessive disorder ataxia-telangiectasia (A-T), characterized by cerebellar degeneration, immunodeficiency and cancer predisposition.","assistant":"[{\"category\": \"DiseaseClass\", \"entity\": \"autosomal recessive disorder\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"A-T\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cerebellar degeneration\"}, {\"category\": \"DiseaseClass\", \"entity\": \"immunodeficiency\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancer predisposition\"}]"},{"user":"A-T carriers were reported to be moderately cancer-prone.A wide variety of A-T mutations, most of which are unique to single families, were identified in various ethnic groups, precluding carrier screening with mutation-specific assays.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"A-T\"}, {\"category\": \"DiseaseClass\", \"entity\": \"cancer-prone\"}, {\"category\": \"Modifier\", \"entity\": \"A-T\"}]"},{"user":"However, a single mutation was observed in 32\/33 defective ATM alleles in Jewish A-T families of North African origin, coming from various regions of Morocco and Tunisia.This mutation, 103C-- > T, results in a stop codon at position 35 of the ATM protein.In keeping with the nature of this mutation, various antibodies directed against the ATM protein failed to defect this protein in patient cells.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"A-T\"}]"},{"user":"A rapid carrier detection assay detected this mutation in three out of 488 ATM alleles of Jewish Moroccan or Tunisian origin.This founder effect provides a unique opportunity for population-based screening for A-T\nMutations associated with variant phenotypes in ataxia-telangiectasia.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"A-T\"}, {\"category\": \"SpecificDisease\", \"entity\": \"ataxia-telangiectasia\"}]"},{"user":"We have identified 14 families with ataxia-telangiectasia (A-T) in which mutation of the ATM gene is associated with a less severe clinical and cellular phenotype (approximately 10% -15% of A-T families identified in the United Kingdom).In 10 of these families, all the homozygotes have a 137-bp insertion in their cDNA caused by a point mutation in a sequence resembling a splice-donor site.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"ataxia-telangiectasia\"}, {\"category\": \"SpecificDisease\", \"entity\": \"A-T\"}, {\"category\": \"Modifier\", \"entity\": \"A-T\"}]"},{"user":"The second A-T allele has a different mutation in each patient.We show that the less severe phenotype in these patients is caused by some degree of normal splicing, which occurs as an alternative product from the insertion-containing allele.The level of the 137-bp PCR product containing the insertion was lowest in two patients who showed a later onset of cerebellar ataxia.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"A-T\"}, {\"category\": \"SpecificDisease\", \"entity\": \"cerebellar ataxia\"}]"},{"user":"A further four families who do not have this insertion have been identified.Mutations detected in two of four of these are missense mutations, normally rare in A-T patients.The demonstration of mutations giving rise to a slightly milder phenotype in A-T\nCleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract.","assistant":"[{\"category\": \"Modifier\", \"entity\": \"A-T\"}, {\"category\": \"SpecificDisease\", \"entity\": \"A-T\"}]"},{"user":"Apoptosis has recently been recognized as a mode of cell death in Huntington disease (HD).Apopain, a human counterpart of the nematode cysteine protease death-gene product, CED-3, has a key role in proteolytic events leading to apoptosis.Here we show that apoptotic extracts and apopain itself specifically cleave the HD gene product, huntingtin.","assistant":"[{\"category\": \"SpecificDisease\", \"entity\": \"Huntington disease\"}, {\"category\": \"SpecificDisease\", \"entity\": \"HD\"}, {\"category\": \"Modifier\", \"entity\": \"HD\"}]"}]